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Arrhythmogenic cardiomyopathy (AC) is a hereditary car-diomyopathy that manifests with ventricular arrhythmias, 
sudden cardiac death, and heart failure.1,2 The pathological hall-
mark of AC is a gradual and progressive replacement of cardiac 
myocytes by fibro-adipocytes, which classically shows a predi-
lection toward involvement of the right ventricle and, hence, the 
term arrhythmogenic right ventricular cardiomyopathy.3,4 AC is 
an enigmatic disease with an inadequately understood patho-
genesis. Recent molecular genetic discoveries have led to partial 
elucidation of the causal genes and identification of mutations 
in genes encoding the protein constituents of the intercalated 
disks (IDs).5–9 IDs are cell–cell adhesion structures composed of 
desmosomes, adherens junctions, and gap junctions. IDs not only 
provide mechanical integrity to the myocardium but also control 
contact-regulated signal transduction.10 Mutations in Lamin A/C 
and transmembrane protein 43 are also associated with AC.11,12 
Overall, PKP2 gene encoding plakophilin 2 (PKP2), a constitu-
ent of the IDs, is the most common causal gene for AC.13,14
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The molecular links between the mutant causal proteins 
and the ensuing cardiac phenotype in AC are not fully known. 
Extensive molecular remodeling of the IDs in AC impairs 
mechanotransduction and is associated with activation of the 
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Rationale: PKP2, encoding plakophilin 2 (PKP2), is the most common causal gene for arrhythmogenic 
cardiomyopathy.
Objective: To characterize miRNA expression profile in PKP2-deficient cells.
Methods and Results: Control and PKP2-knockdown HL-1 (HL-1Pkp2-shRNA) cells were screened for 750 miRNAs 
using low-density microfluidic panels. Fifty-nine miRNAs were differentially expressed. MiR-184 was the 
most downregulated miRNA. Expression of miR-184 in the heart and cardiac myocyte was developmentally 
downregulated and was low in mature myocytes. MicroRNA-184 was predominantly expressed in cardiac 
mesenchymal progenitor cells. Knockdown of Pkp2 in cardiac mesenchymal progenitor cells also reduced miR-
184 levels. Expression of miR-184 was transcriptionally regulated by the E2F1 pathway, which was suppressed in 
PKP2-deficient cells. Activation of E2F1, on overexpression of its activator CCND1 (cyclin D1) or knockdown of its 
inhibitor retinoblastoma 1, partially rescued miR-184 levels. In addition, DNA methyltransferase-1 was recruited 
to the promoter region of miR-184, and the CpG sites at the upstream region of miR-184 were hypermethylated. 
Treatment with 5-aza-2′-deoxycytidine, a demethylation agent, and knockdown of DNA methyltransferase-1 
partially rescued miR-184 level. Pathway analysis of paired miR-184:mRNA targets identified cell proliferation, 
differentiation, and death as the main affected biological processes. Knockdown of miR-184 in HL-1 cells and 
mesenchymal progenitor cells induced and, conversely, its overexpression attenuated adipogenesis.
Conclusions: PKP2 deficiency leads to suppression of the E2F1 pathway and hypermethylation of the CpG sites 
at miR-184 promoter, resulting in downregulation of miR-184 levels. Suppression of miR-184 enhances and its 
activation attenuates adipogenesis in vitro. Thus, miR-184 contributes to the pathogenesis of adipogenesis in 
PKP2-deficient cells.  (Circ Res. 2016;119:731-750. DOI: 10.1161/CIRCRESAHA.116.308422.)
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Hippo pathway, a contact-regulated signaling pathway in-
volved in cellular growth, differentiation, and proliferation.15 
Activation of the Hippo pathway results in suppression of gene 
expression through its downstream effector, the Yes-associated 
protein–TEA domain family member (YAP–TEAD) complex, 
as well as suppression of the canonical Wnt signaling through 
the β catenin (CTNNB1)-TCF7L2 (transcription factor 7-like 
2 [T cell–specific, HMG-box]) transcriptional machinery.15–17 
Collectively, these cell-signaling events impart transcriptional 
changes that regulate cell growth, proliferation, and differen-
tiation, leading to phenotypic expression of AC.15
MicroRNAs (miRNAs) are small 22 nucleotide molecules 
that regulate gene expression and impact various biological 
processes, including cardiac hypertrophy, myocyte differen-
tiation, and proliferation..18–20 MiRNAs are largely nudgers 
and tweakers of genome management because their effects on 
transcript levels, by-and-large, are modest.21 Because of mul-
tiplicity of their targets, however, miRNAs influence various 
molecular networks and biological processes.20,22–30 MiRNAs 
are also targets of various signaling pathways, including Hippo 
and the canonical Wnt pathways, which are implicated in 
AC.20,22–30 Moreover, miRNAs are implicated in the pathogene-
sis of heart failure, fibrosis, and adipogenesis,18,31–33 phenotypes 
typically observed in patients with cardiomyopathies.2–4 Thus, 
we hypothesized that miRNAs are also involved in the patho-
genesis of AC. To test this hypothesis, we screened for the dif-
ferentially expressed miRNAs and characterized functional 
and biological effects of the most downregulated miRNA in 
HL-1 and cardiac mesenchymal progenitor cells (MPCs).
Methods
An expanded version of Material and Methods is provided as Online 
Data Supplement.
Recombinant Viral Constructs
Recombinant lentiviruses were generated as published.15 The miR-
Zip vector contained short hairpin RNAs (shRNAs) positioned in 
tandem with a GFP expression cassette downstream to an H1 pro-
moter. MiR-184 overexpression vector contained a 500-bp genom-
ic fragment of miR-184 in the miR-Express vector. Commercially 
available lentiviruses expressing shRNAs against target transcripts 
and prepackaged recombinant adenoviral constructs were used. HL-1 
cells at 70% to 90% confluence were transduced with the recombi-
nant viruses. Transduction efficiency was determined by detecting the 
GFP signal under fluorescence microscopy, fluorescence-activated 
cell sorter analysis, and quantification of the target transcript levels.
Suppression of Expression of PKP2 in the HL-1 Cells
Two independent PKP2-deficient HL-1 lines (HL-1Pkp2-shRNA) were es-
tablished using 2 different shRNAs, as published.15 Knockdown of 
Pkp2 mRNA and PKP2 protein levels were detected by quantitative 
polymerase chain reaction (qPCR) and immunoblotting, respectively.
Isolation of Cardiac Myocytes and MPCs
To isolate cardiac myocytes, explanted hearts were perfused with a 
Ca2+-free perfusion buffer and subjected to digestion in a collagenase 
buffer. Myocytes were dissociated and gravity precipitated in the 
presence of 200 mmol/L ATP and centrifugation at 20g. The isolated 
myocytes were reintroduced to increasing concentrations of calcium 
at a final concentration of 1.5 mmol/L of CaCl2 and placed in culture 
dishes or cover glasses coated with laminin.
Cardiac MPCs were isolated by sorting of nonmyocyte fraction of 
cardiac cells against anti-CD44 and antiplatelet-derived growth factor 
α (PDGFRA) antibodies, per published protocols.34–36
Mouse Models of AC
Myh6:JupTr mice have been published.16,37,38 To knock down Pkp2 
gene in the heart, an shRNA targeting the Pkp2 mRNA (position 
1154–1174) was cloned into the U6-LoxP-Neo vector.39,40 Nkx2-
5:Cre deleter mice was used to remove a LoxP neo cassette and 
conditionally activate expression of the shRNA against Pkp2 mRNA 
(Pkp2shRNA) in the cardiogenic lineage.41
MicroRNA Expression Profiling
Expression profile of miRNAs was determined using TaqMan low-
density array microfluidic cards (Rodent miRNA v3.0 Card A and 
Card B; Applied Biosystems). The panels contain a total of 750 ma-
ture miRNAs of which 641 are annotated and curated in the mouse 
genome. Mouse small nucleolar RNA (MammU6) was used for data 
normalization and relative quantification because it was spotted 3 
times in each card, as opposed to other controls. In brief, aliquots of 
RNA isolated from the HL-1 and HL-1Pkp2-shRNA cells from 2 indepen-
dent experiments were reverse-transcribed into cDNAs and amplified 
by qPCR. MiRNAs with Ct values of >35 were excluded.
Immunoblotting and Immunofluorescence Staining
Immunoblotting and immunofluorescence were performed as per the 
conventional methods.15,36 The list of the primary and secondary anti-
bodies used is provided in the Online Table I.
In Situ Hybridization
In situ hybridization was performed as per a published protocol.42 In 
brief, thin myocardial sections were hybridized with a 5′ and 3′ dual 
DIG-labeled detection probe against miR-184 or a control scrambled 
probe. Sections were washed in PBS after overnight hybridization, 
mounted, and examined under light microscopy.
Quantitative PCR
Total RNA (including miRNA) was extracted and reverse transcribed. 
MiRNAs were amplified using specific TaqMan gene expression as-
says and TaqMan MicroRNA assays (Online Table I). Gapdh and 
snoRNA202 transcript levels were used for normalization for mRNA 
and miRNA levels, respectively. 2ΔΔCt method was used to calculate 
the normalized gene expression values.
MicroRNA Targets and miRNA–mRNA Pairing
Global gene expression patterns were determined by whole transcrip-
tome sequencing, as published.15 Predicted miR-184 targets were 
identified using miRWalk online software (www.umm.uni-heidelberg.
Nonstandard Abbreviations and Acronyms
5-aza-D 5-aza-2′-deoxycytidine
AC arrhythmogenic cardiomyopathy
Agpat1 acylglycerolphosphate acyltransferase
Agpat3 acylglycerolphosphate acyltransferase
DNMT DNA methyltransferase
FABP4 fatty acid–binding protein 4
IDs intercalated disk
JUP junction plakoglobin
MPCs mesenchymal progenitor cells
miR microRNA
PDGFRA platelet-derived growth factor α
PKP2 plakophilin-2
PPARG peroxisome proliferator-activated receptor gamma
RB1 retinoblastoma 1
RNA-Seq RNA sequencing
ShRNA short hairpin RNA
TCF7L2 transcription factor 7-like 2 (T cell–specific, HMG-box)
TEAD TEA domain family member (SV40 transcriptional enhancer 
factor)
YAP Yes-associated protein
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de/apps/zmf/mirwalk/). Genes that were identified as targets in at 
least 2 different databases were analyzed. MiRNA–mRNA pairing 
was performed using the ingenuity pathway analysis software (www.
ingenuity.com). All putative targets of miR-184 were identified using 
the miRwalk and ingenuity pathway analysis software. Targets that 
were identified by at least 2 programs and had a seed length of 6 nu-
cleotides or longer were included for further analyses. The candidate 
target mRNAs and differentially expressed mRNAs were matched, 
and those mRNAs that had a minimum fragments per kilobase of 
transcript per million fragments mapped value of 1 in at least one 
sample and showed a reciprocal expression to its corresponding miR-
NA were considered as targets. Finally, target gene expression cutoff 
was set at 1.2-fold expression, and the q value at 0.05. To examine 
the potential biological significance of paired changes, gene ontol-
ogy over-representation analysis, upstream regulator, and canonical 
pathway analyses were performed using ingenuity pathway analysis.
Adiogenesis Network Analysis
A protein functional association network was constructed for miR-
184 targets that were involved in adipogenesis, namely, AGPAT1, 
AGPAT3, NCOA1, and peroxisome proliferator-activated receptor 
gamma (PPARG)C1B, using the STRING online tool. The medium 
confidence score for interaction was set at 0.4, and the option for 
all active prediction method was included. Direct interactions are de-
picted as colored nodes in the Network. Gene that are identified as 
members of the network and were found to be upregulated in the 
HL-1Pkp2-shRNA cells in RNA-sequencing data were further validated to 
build an miR-184 target network for adipogenesis.
Adipogenesis
Induction and quantification of adipogenesis in the HL-1 cells and MPCs 
cells were as described.15 In brief, ≈5×104 HL-1 cells or MPCs were 
treated with an adipogenesis induction medium for 7 to 14 days. qPCR 
and immunoblotting were used to quantify transcript and protein levels 
of selected genes that regulate adipogenesis, respectively. Accumulation 
of fat droplets was assessed by Oil Red O staining and expression of 
adipogenic transcription factors CEBPA (CCAAT/enhancer binding 
protein alpha) and PPARG expression by immunofluorescence.
Activation and Suppression of Selected Signaling 
Pathways
To determine the effect of activation of the E2F signaling pathway on 
miR-184 levels, HL-1 cells were transduced with recombinant adeno-
viruses expressing CCND1 (cyclin D1). Likewise, a siRNA construct 
was used to target retinoblastoma (RB1), an inhibitor of E2F1 path-
way. Control viruses and viruses expressing no-target or scrambled 
shRNAs and nontargeting siRNAs were included as controls.
To activate the canonical Wnt signaling, cells were treated with 
Wnt-3A at 40, 80, and 120 ng/mL for 24 hours. To suppress the canon-
ical Wnt signaling pathway, HL-1 cells were transduced with recombi-
nant lentiviruses expressing shRNA against Tcf7l2 (Lenti:Tcf7l2shRNA). 
Activation or suppression of the canonical Wnt signaling pathway was 
also confirmed by quantifying protein levels of TCF7L2, mRNA lev-
els of Axin2 and Ccnd1, and a Tcf7l2-luciferase reporter assay.
To activate gene expression through the Hippo pathway, HL-1 
cells were treated with 1 μmol/L of 1-Oleoyl lysophosphatidic acid 
for 1, 2, and 4 hours. To suppress gene expression through the Hippo 
pathway, cells were transduced with the recombinant lentiviruses 
expressing an shRNA against Yap (Lenti:YapshRNA). Activity state of 
the Hippo pathway was confirmed by quantifying levels of YAP pro-
tein by immunoblotting, mRNA levels of target transcripts Ctgf and 
Cry61 by qPCR, and a TEAD luciferase assay.
DNA Methylation Assay
To determine whether suppression of miR-184 was a consequence of 
DNA methylation–dependent epigenetic silencing of the locus, the ge-
nomic sequence upstream of the pre-miR-184 transcription start site 
was analyzed for the presence of CpG-rich regions. Using EMBOSS 
Cpgplot (http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/), 15 
CpG sites with observed/expected ratio of >0.60, located 500- to 800-
bp upstream to the pre-miRNA start site, were identified. This region 
was used for DNA methylation analysis by bisulfite conversion, clon-
ing, and sequencing of individual clones. Genomic DNA was extracted 
from the HL-1 and HL-1Pkp2-shRNA cells, treated for bisulfite conversion, 
and PCR-amplified using primers specific to the miR-184 upstream 
region (Online Table I). PCR products were cloned using a TA cloning 
strategy and then sequenced. Methylation of CpG sites was analyzed 
using QUMA online tool (http://quma.cdb.riken.jp/).
To determine effects of DNA methylation, Dnmt1 was knocked 
down using recombinant lentiviruses expressing respective shRNAs, 
as described earlier.
Statistics
Data were presented as mean±SD. Differences in the continuous variables 
between the 2 groups were compared by t test or Mann–Whitney U test 
and among multiple groups by 1-way ANOVA. Whenever applicable, 
multiple groups Dunnett’s corrected P values for pairwise comparisons 
were presented. Differences among the categorical values were compared 
by Kruskall–Wallis test. Statistical significance for methylation at each 
CpG sites was calculated by Fisher exact test (QUMA online tool).
Results
Differentially Expressed miRNAs in HL-1Pkp2-shRNA 
Cells
Two independent lines of HL-1Pkp2-shRNA were generated us-
ing 2 different sets of shRNAs that target Pkp2 transcript 
(Figure 1A). qPCR showed reduced Pkp2 mRNA levels by 
3.7±0.5-fold (shRNA no 1, N=6; P<0.001) and 2.4±0.4-fold 
(shRNA no 2, N=5; P<0.001), as compared with control 
HL-1 cells (Figure 1B). Likewise, PKP2 protein levels were 
reduced by 81.1±10.4% (shRNA no 1, N=5; P<0.0001) and 
77.8±15.6% (shRNA no 2, N=5; P<0.0001), as compared 
with control cells (Figure 1C and 1D).
To identify differentially expressed miRNAs in the HL-
1Pkp2-shRNA cells, miRNAs were screened using TaqMan low-
density array microfluidic panels comprising 641 unique 
miRNAs. A total of 292 miRNAs were expressed in the HL-1 
cells at a threshold Ct value of ≤35. Thirty-one miRNAs were 
upregulated, 28 were downregulated, and 233 were unchanged 
in the HL-1Pkp2-shRNA cells as compared with control HL-1 cells 
(Figure 1E and 1F; Online Table II).
MiR-200b, miR-487b, and miR-429 were the most upreg-
ulated, whereas miR-184 and miR-881 were the most down-
regulated miRNAs (Figure 1F). MiR-184, an independently 
transcribed miRNA, was the most downregulated miRNA 
in both lines of HL-1Pkp2-shRNA cells (Figure 1E, 1F, and 1G). 
It was reduced by more than ≈14-fold (N=24; P<0.0001). 
Likewise, transcript levels of miR-881 were reduced by 
64.14±19.9% in the HL-1Pkp2-shRNA cells (P<0.0001). qPCR 
validation of top upregulated miRNAs showed that miR-200b 
levels were increased by 7.99±0.27 (N=4; P<0.0001) and 
miR-429 by 7.98±0.37 (N=4; P<0.0001) in the HL-1Pkp2-shRNA 
cells (Figure 1H). Given robust and consistent downregula-
tion of miR-184 levels in the PKP2-deficient HL-1 cells and in 
view of a paucity of data on the biological functions of miR-
184 in the heart, it was further characterized.
Generation and Characterization of an Nkx2.5-
Cre:Pkp2shRNA Mouse Model of AC
To extend the in vitro findings to in vivo models of AC, expres-
sion of PKP2, the most common causal gene for AC,13,14 was 
conditionally knocked down in the mouse heart on expression 
of an shRNA against Pkp2 mRNA, under the transcriptional 
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regulation of the Nkx2-5 locus (Figure 2A). Pkp2 mRNA 
and PKP2 protein levels were reduced by 41±10% and 
54±21%, respectively, in the Nkx2.5-Cre:Pkp2shRNA mice, as 
compared with wild-type mice (Figure 2B–2D). The Nkx2.5-
Cre:Pkp2shRNA mice survived normally but exhibited signifi-
cantly enlarged left ventricle and decreased cardiac systolic 
Figure 1. Differentially expressed microRNA (miRNAs) in arrhythmogenic cardiomyopathy (AC) models. A, Schematic 
representation of shRNA constructs used to knockdown Pkp2 in the HL-1 (HL-1Pkp2-shRNA) cells. B, Quantitative polymerase chain reaction 
(qPCR) analysis of Pkp2 mRNA in HL-1 cells expressing 2 independent shRNAs targeting Pkp2. An shRNA with no targeting site in 
the mammalian genome (NT-shRNA) was used as a control (N=6 per group; P<0.0001 between HL-1 and HL-1Pkp2-shRNA1 or HL-1Pkp2-
shRNA2 and P=0.27 between nontransduced HL-1 and HL-1 cells transduced with NT-shRNA by Dunnett’s multiple comparisons test). 
There were no differences in the expression levels of Pkp2 or selected genes, including miRNAs between the NT-shRNA and HL-1 
control cells. Therefore, control PKP2-competent HL-1 cells were used as control. C and D, Immunoblots (IB) and quantification graph 
showing suppression of PKP2 protein in the HL-1Pkp2-shRNA cells (N=5 per group; P<0.0001 between control cells and cells transduced 
with shRNA1 and 2 constructs and P=0.8 for nontransduced cells vs cells transduced with the NT-shRNA construct). E, Volcano plot of 
Taqman low-density array data showing log 2-fold change vs −log P values for all miRNAs in control HL-1 vs HL-1Pkp2-shRNA cells. MiR-
184, the most differentially expressed miRNA (16-fold downregulation in the HL-1Pkp2-shRNA cells), is marked. F, Heat map of differentially 
expressed miRNAs (a 2-fold change cutoff point) between control HL-1 and HL-1Pkp2-shRNA cells. G, qPCR data showing suppressed miR-
184 expression levels in 2 independent lines of HL-1Pkp2-shRNA cells (fshRNA no 1 vs control: 5.86±4.5-fold, N=7, P<0.0001 and shRNA 
no 2 vs control, 14.2±9.2-fold, N=24, P<0.001). H, qPCR confirming reduced levels of miR-881 and increased levels of miR-200b and 
miR-429 in the HL-1Pkp2-shRNA cells (N=4–6 per group and all P values <0.001). cPPT indicates central polypurine tract; hPGK, human 
phosphoglycerate kinase; PKP2, plakophilin 2; shRNA, short hairpin RNA; and TUBA1B, tubulin alpha 1B.
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Figure 2. Pkp2 knockdown mouse model of arrhythmogenic cardiomyopathy (AC). A, Schematic representation of the shRNA 
construct used to knock down PKP2 conditionally in the mouse heart. B, Quantitative polymerase chain reaction (qPCR) data showing 
efficient Pkp2 mRNA knockdown in the heart in the Nkx2.5-Cre:Pkp2shRNA mice as compared with wild-type (WT) control (41±10%, 
N=19; P<0.0001). C and D, Immunoblots (IB) and quantification graph showing suppression of PKP2 protein in the Nkx2.5-Cre:Pkp2shRNA 
mice, as compared with WT control (54±21%, N=5; P=0.005). E and F, Thin myocardial sections stained for Picro-Sirius Red showing 
increased fibrosis in the Nkx2.5-Cre:Pkp2shRNA mouse hearts, as compared with WT mice (2.1±1.1-fold increase, N=5 WT and 16 Nkx2.5-
Cre:Pkp2shRNA mice). G and H, Oil Red O (ORO)–stained thin myocardial sections and quantitative data, respectively, showing increased 
number of adipocytes in the heart of Nkx2.5-Cre:Pkp2shRNA mice (5.1±3.4-fold, N=5–7 per group). I and J, Data showing reduced levels of 
miR-184 in 2 independent mouse models of AC. MiR-184 levels were reduced in the PKP2-deficient mice (Nkx2-5-CrePkp2-shRNA, 2.2±0.97-
fold, N=8 per group; P=0.0001) and mice expressing a truncated junction protein plakoglobin (Myh6:JupTr, 1.99±0.63-fold, N=6 per group; 
P<0.0001). CVF indicates collagen volume fraction; PKP2, plakophilin 2; shRNA, short hairpin RNA; and TUBA1B, tubulin alpha 1B.
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Figure 3. Expression and developmental downregulation of miR-184 in the heart and cardiac mesenchymal progenitor cells 
(MPCs). A, In situ hybridization showing expression and progressive reduction in miR-184 levels in E16.5, P3, and P90 hearts.  
B, Quantitative polymerase chain reaction (qPCR) data showing progressive downregulation of miR-184 levels in E16.5, P3, P21, and P90 
hearts (N=4–6 per group; P<0.001 for all groups compared with E16.5 group, P<0.001 between P90 and E16.5, P=0.002 (Continued )  
 by guest on February 20, 2018
http://circres.ahajournals.org/
D
ow
nloaded from
 
Gurha et al  miR-184 and Adipogenesis  737
function (Online Table III). Right ventricular function could 
not be reliable evaluated by echocardiography. Interstitial 
fibrosis was increased by 2.1±1.2-fold (Figure 2E and 2F). 
Likewise, the number of cells accumulating fat droplets was 
increased by 5.1±3.5-fold (N=7; P=0.037) in the hearts of 
Nkx2.5-Cre:Pkp2shRNA mice (Figure 2G and 2H). The observed 
phenotype is similar to that in the previously described mouse 
models of AC.16,37
Suppressed miR-184 Levels in Independent Mouse 
Models of AC
Expression levels of miRNA-184 were determined by qPCR 
in the heart of the Nkx2.5-Cre:Pkp2shRNA and the Myh6-JupTr 
mice.37 Levels of miR-184 were reduced by 52±21% in the 
hearts of 4-week-old Nkx2.5-Cre:Pkp2shRNA mice (Figure 2I, 
N=9; P=0.004) and by 49±10% (N=6, P=0.0048) in the hearts 
of Myh6:JupTr mice compared with age- and sex-matched 
wild-type mouse hearts (Figure 2J).
Developmental Downregulation of miR-184 
Expression in the Heart
In situ hybridization detected expression of miR-184 in E16.5, 
P3, and P90 hearts (Figure 3A). MiR-184 was abundantly ex-
pressed in the embryonic hearts and exhibited progressive down-
regulation from embryonic to P90 adult hearts (Figure 3A). To 
further quantify miR-184 levels during cardiac myocyte differ-
entiation, its levels were quantified in E16.5, P3, P21, and P90 
hearts. As shown in Figure 3B, miR-184 levels were ≈100-fold 
higher in E16.5 hearts than in P90 adult hearts and were progres-
sively reduced in E16.5, P3, P21, and P90 hearts (Figure 3B).
Differential Downregulation of miR-184 in Cardiac 
Myocytes Isolated From the Nkx2.5-Cre:Pkp2shRNA 
Mice
To further corroborate differential expression of miR-184 in 
AC, cardiac myocytes were isolated from P3, P21, and P90 
wild-type and Nkx2.5-Cre:Pkp2shRNA mice. Levels of Pkp2 
mRNA were reduced by 40% to 50% in cardiac myocytes 
isolated from the heart of Nkx2.5-Cre:Pkp2shRNA mice as com-
pared with wild-type mice at all 3 stages of development 
(Online Figure IA). MiR-184 levels were the highest in the 
neonatal (P3) cardiac myocytes, intermediary in P21 cardiac 
myocytes (4-fold reduction from P3 to P21), and the lowest 
in P90 cardiac myocytes (10-fold reduction; Online Figure 
IB). Developmental downregulation of miR-184 expression in 
cardiac myocytes was differential between the wild-type and 
the Nkx2.5-Cre:Pkp2shRNA mice because miR-184 levels were 
consistently lower by ≈40% in cardiac myocytes isolated from 
the Nkx2.5-Cre:Pkp2shRNA mice in all 3 development ages as 
compared with the corresponding levels in the wild-type mice 
(Online Figure IB).
Expression of miR-184, PKP2, and NKX2-5 in 
Cardiac MPCs
Given that miR-184 was expressed at higher levels in imma-
ture cardiac cells and was downregulated in mature myocytes, 
we quantified miR-184 levels in cardiac MPCs, identified as 
Linneg;PDGFRApos:CD44pos cells. Consistent with the higher 
expression levels of miR-184 in the embryonic heart and im-
mature myocytes, miR-184 levels were higher (249.4±57.17-
fold) in cardiac MPCs as compared with isolated P90 cardiac 
myocytes (Figure 3C).
To determine whether PKP2 is also expressed in cardiac 
MPCs, in addition to cardiac myocytes, MPCs were isolated 
from the hearts of wild-type mice and stained for the expression 
of PKP2. Likewise, isolated cardiac MPCs were also stained for 
the expression of NKX2-5, which drives expression of an shR-
NA against Pkp2 transcript in the Nkx2.5-Cre:Pkp2shRNA mice. 
Consistent with our recent data on the expression of desmosome 
proteins in nonmyocyte cells in the heart,36 PKP2 as well as 
NKX2-5 were expressed in isolated cardiac MPCs (Figure 3D). 
Quantitatively 33.45±17.13% of cardiac MPCs express PKP2, 
30.0±5.9% express NKX2-5, and only 21.2±6.3% of MPCs 
stained for both PKP2 and NKX2.5 (Figure 3E).
Given heterogeneous expression of PKP2 in cardiac 
MPCs, to further define the role of miR-184 in differentiation 
of cardiac MPCs to adipocytes, Pkp2 transcript was targeted 
in isolated cardiac MPCs, using 2 sets of lentiviruses express-
ing distinct Pkp2-specific shRNAs (Figure 3F). Knockdown 
of Pkp2 with both shRNAs (85±6.4% with shRNA1 and 
61.2±9.5% with shRNA2) was associated with reduced ex-
pression levels of miR-184 (46±26% and 33.6±27%, respec-
tively) in cardiac MPCs (Figure 3F and 3G).
Regulation of Expression of miR-184 by the E2F1 
Pathway
To gain insights into the mechanisms responsible for downregu-
lation of miR-184 in the AC models, we analyzed differentially 
expressed transcripts in the HL-1Pkp2-shRNA cells by RNA sequenc-
ing.15 Pathway analysis led to identification of multiple perturbed 
signaling pathways, including the Hippo, canonical Wnt, and in-
tegrin signaling pathways in the HL-1Pkp2-shRNA cells.15 Notable 
among the target genes was Ccnd1, whose expression was con-
sistently reduced by >10-fold. CCND1 is a regulatory subunit of 
cyclin-dependent kinases 4 and 6, which target RB1 for inacti-
vation by phosphorylation and, hence, removal of the inhibitory 
effects of RB1 on E2F transcription factors (Online Figure II). 
Thus, a dramatic reduction in Ccnd1 expression is expected to 
lead to activation of RB1 and suppression of the E2F1 pathway. 
In accord with the above, gene set enrichment analysis showed 
significant downregulation of the E2F1 targets (Figure 4A). 
Likewise, E2F1 target genes were significantly downregulated in 
Figure 3 Continued. between P90 and P3, and P=0.1 between P90 and P21). C, Expression levels of miR-184 in cardiac MPCs 
showing 249.4±57.17-fold higher levels in cardiac MPCs, as compared with adult cardiac myocytes (N=5; P<0.0001). D, Expression of 
PKP2 (green) and NKX2-5 (red) in isolated cardiac MPCs, as detected by immunofluorescence staining. E, Quantitative data showing 
33.45±17.13% of cardiac MPC expressing PKP2, 30.0±5.9% expressing NKX2-5, and 21.2±6.3% expressing both PKP2 and NKX2-5.  
F, Knockdown of Pkp2 in cardiac MPCs using 2 independent sets of shRNAs. Pkp2 mRNA levels were reduced by 85±6.4% and 
61.2±9.5% with shRNAs 1 and 2, respectively (N=4 per each set; P<0.0001 for each knockdown groups compared with nontransduced 
cells). G, Reduced miR-184 transcript levels on knockdown of Pkp2 in 2 independent lines in cardiac MPCs (N=4; P=0.03 and P=0.02 
for pairwise comparisons between the control and Pkp2-shRNA1 groups and P=0.10 between control and Pkp2-shRNA1 groups). The 
control NT-shRNA vector had a backbone identical to that in the viral constructs used to suppress Pkp2 expression. NKX indicates NK2 
homeobox 5; NT, no target; PKP2, plakophilin 2; and shRNA, short hairpin RNA.
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Figure 4. Regulation of miR-184 levels by E2F1 transcription factor. A, Gene set enrichment analysis (GSEA) of the differentially 
expressed transcripts between wild-type (WT) HL-1 and HL-1Pkp2-shRNA cells showing a significant enrichment of the E2F1 target genes.  
B, Heat map of E2F enrichment profile showing the predominantly downregulated transcripts (false discovery rate [FDR] is (Continued )  
 by guest on February 20, 2018
http://circres.ahajournals.org/
D
ow
nloaded from
 
Gurha et al  miR-184 and Adipogenesis  739
the HL-1Pkp2-shRNA cells (Figure 4B). Consistent with suppressed 
E2F1 transcriptional activity and reduced CCND1 levels, pro-
liferation rate of HL-1Pkp2-shRNA cells was considerably slower as 
compared with wild-type HL-1 cells (Figure 4C).15 To determine 
whether E2F1 directly regulated expression of miR-184, its bind-
ing to the promoter region of miR-184 was analyzed by ChIP 
(chromatin immunoprecipitation) assay. Genomic DNA was 
precipitated with an anti-E2F1 antibody, and miR-184 promoter 
region was amplified by PCR. The finding indicated binding of 
E2F1 transcription factor to the promoter region of miR-184 
(Figure 4D and 4E). To further support the role of E2F1 in tran-
scriptional regulation of miR-184, expression of RB1, an inhibi-
tor of E2F1, was suppressed by siRNA targeting. Suppression of 
Rb1 expression (3.7±0.6) led to an ≈ 2-fold increase in miR-184 
transcript levels (Figure 4F). In a complementary set of studies, 
HL-1Pkp2-shRNA cells were transduced with recombinant adenovi-
ruses expressing CCND1, which activates the E2F1 transcrip-
tion factor pathway. Overexpression of CCND1 in HL-1Pkp2-shRNA 
cells led to a 1.7-fold increase in the miR-184 transcript levels 
(Figure 4G).
Effects of the Hippo Pathway on miR-184 Levels
To determine whether activation of the Hippo pathway, ob-
served in AC,15 was responsible for suppressed miR-184 lev-
els, the Hippo pathway kinases LATS1/2 were inactivated to 
activate gene expression through YAP–TEAD transcription 
factors, on treatment of the cells with 1 μM of lysophosphatid-
ic acid for 1, 2, and 4 hours. Treatment with lysophosphatidic 
acid increased nuclear localization of YAP (Online Figure 
IIIA and IIIB), TEAD transcriptional activity, as detected by 
a luciferase assay (Online Figure IIIC), and YAP–TEAD tar-
get transcript levels (Online Figure IIID). However, despite 
increased YAP–TEAD transcriptional activity, levels of miR-
184 were unchanged (Online Figure IIIE–IIIG).
In a complementary set of studies, the YAP–TEAD com-
plex was transcriptionally inactivated on transduction of the 
HL-1 cells with Lenti:YapshRNA construct, which expresses an 
shRNA against Yap mRNA. YAP protein levels were reduced 
by 41% (Online Figure IIIH), as were the transcript levels of 
its downstream targets Ctgf and Cyr61 (Online Figure III-I). 
However, despite knockdown of the YAP–TEAD transcrip-
tional activity, levels of miR-184 remained unchanged as 
compared with control nontransduced cells or cells transduced 
with a control shRNA (Online Figure IIIJ).
Effects of the Canonical Wnt Signaling Pathway on 
miR-184 Levels
To ascertain whether suppressed canonical Wnt signaling was 
responsible for reduced miR-184 levels, the canonical Wnt 
signaling was activated by treating the HL-1 and HL-1PKP2-
shRNA
 cells with 40, 80, and 120 ng/mL of the purified Wnt-
3A protein. Activation of the canonical Wnt signaling led to 
a dose-dependent increase in the TCF7L2 luciferase activity 
(Online Figure IVA) and levels of selected canonical Wnt tar-
get transcripts Ccnd1 and Axin2 by 2- to 5-fold (Online Figure 
IVB). However, activation of the canonical Wnt signaling had 
no effect on miR-184 levels in the HL-1 cells (Online Figure 
IVC). Likewise, treatment with Wnt-3A increased TFC7L2 
luciferase activity (Online Figure IVD) and levels of the es-
tablished canonical Wnt targets in HL-1Pkp2-shRNA cells (Online 
Figure IVE). MiR-184 levels were increased only modestly 
(1.6-fold, N=5; P=0.06; Online Figure IVF). In a complemen-
tary set of studies, the canonical Wnt signaling was inactivated 
on transduction of the cells with a Lenti:Tcf7l2shRNA construct 
expressing an shRNA targeted to Tcf7l2 transcription factor. 
Lentiviral transduction effectively reduced TCF7L2 protein 
levels by ≈50% in the HL-1 cells (Online Figure IVG) and the 
transcripts levels of canonical Wnt targets Ccnd1 and Axin2 
(Online Figure IVH). However, suppression of the canonical 
Wnt signaling had no discernible effect on the expression lev-
els of miR-184 (Online Figure IV-I).
Effects of miR-184 on Hippo and Canonical Wnt 
Signaling
To determine whether miR-184 was involved in suppression 
of gene expression through the YAP–TEAD and CTNNB1–
TCF7L2 transcription factors, HL-1 cells were transduced 
with Lenti-miR-184shRNA or Lenti-pre-miR-184 constructs to 
knock down or overexpress miR-184 in HL-1 cells, respective-
ly (Online VA–VG). Transduction efficiency was determined 
by flow cytometric analysis of cells expressing the reporter 
protein GFP (Online Figure VD and VE). Knockdown and 
overexpression of miR-184 were verified by quantification of 
miR-184 transcript levels (Online Figure VF and VG). Neither 
suppression nor increased expression of miR-184 had any ef-
fects on expression levels of selected targets of the Hippo 
(TEAD-YAP) and canonical Wnt (CTNNB1-TCF7L2) signal-
ing pathways (Online Figure VH and V-I).
Epigenetic Silencing of the miR-184 Locus by 
Hypermethylation
Because activation of E2F1 only partially rescued miR-184 
levels and given that modulation of the Hippo and canonical 
Wnt had no significant effect on miR-184 expression, we sur-
mised that additional mechanism(s) might contribute to sup-
pressed miR-184 levels in the HL-1Pkp2-shRNA cells. The E2F/
RB1 complex is known to recruit DNA methyltransferases 
(DNMTs) to gene promoters.43 Given that miR-184 resides 
Figure 4 Continued. set at 0.01). C, Proliferation rate of wild-type and HL-1Pkp2-shRNA cells, as determined by CellTiter Blue assay. Dotted 
lines show the growth curves at 4 different time points and straight lines the linear regression fit depicting slope of each curve (m value). 
D, Agarose gel electrophoresis photograph showing a 160-bp miR-184 5′ genomic region amplified after precipitation of DNA with an 
anti-E2F1 antibody in a ChIP assay. E, Quantitative data showing precipitated 5′ genomic region of miR-184 relative to input in the ChIP 
assay. F, Rescue of miR-184 levels on siRNA-mediated knockdown of retinoblastoma 1 (RB1) in HL-1 cells. Cells treated with a scrambled 
siRNA are included as controls. As shown, Rb1 transcript levels were reduced by 3.7±0.6-fold compared with control nontransfected cells 
(N=3 per group; P=0.0002). Right, Increased miR-184 levels by 1.95±0.56 on knockdown of Rb1 (N=3; P=0.024). G, Rescue of miR-184 
on overexpression of CCND1, which activates the E2F1 pathway and inactivates RB on phosphorylation by CDK4/6. Levels of Ccnd1 
mRNA were increased by 236±85-fold on transduction of HL-1 cells with recombinant adenoviruses, as shown in the graph to the left (N=3; 
P<0.001). In accord with increased Ccnd1 levels, miR-184 levels were changed in a similar direction and increased by 1.74±0.38-fold (N=4; 
P=0.005). CCND1 indicates cyclin D1; ChIP, chromatin immunoprecipitation; CMV, cytomegalovirus; E2F1, E2F transcription factor 1; IP, 
immunoprecipitation; MW, molecular weight; PKP2, plakophilin 2; and shRNA, short hairpin RNA.
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Figure 5. Epigenetic regulation of miR-184 in arrhythmogenic cardiomyopathy (AC). A, Position of the CpG sites at the upstream 
regulatory genomic locus of miR-184. B and C, Analysis of DNA methylation at the mouse miR-184 locus by sodium bisulfite treatment 
and sequencing of PCR clones from HL-1 (B) and HL-1Pkp2-shRNA cells (C). Each row represents CpG methylation status of a randomly 
selected independent clone. D, Bar graph showing percent methylation of all CpG site in HL-1 and HL-1Pkp2-shRNA cells. All analyzed CpG 
sites show significant hypermethylation in the HL-1Pkp2-shRNA cells as compared with HL-1 cells alone (*P<0.01 and **P<0.001). E, Effects 
of treatment of HL-1 and HL-1Pkp2-shRNA cells with 10 μm 5-aza-2′-deoxycytidine (5-azaD) on miR-184 levels determined daily. MiR-184 
levels were increased after treatment with 5-azaD in both HL-1 and HL-1Pkp2-shRNA cells at 5 days post aza-C treatment. Magnitude of the 
induction in the HL-1Pkp2-shRNA was greater than that in the HL-1 cells (N=3, P<0.01). F, Photograph of agarose gel showing (Continued )  
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in an imprinted locus, regulated by methyl-CpG–binding do-
main protein 1 and methyl-CpG–binding protein 2, we de-
termined methylation state of miR-184 5′ genomic region. A 
total of 15 CpG-rich regions were identified in the upstream 
regulatory region of miR-184 locus, which were screened for 
methylation (Figure 5A). Bisulfite conversion, cloning, and 
sequencing showed that the CpG sites were predominantly 
unmethylated in the control HL-1 cells (Figure 5B). In con-
trast, the vast majority of the CpG sites were hypermethyl-
ated in HL-1Pkp2-shRNA cells (Figure 5C). On average, HL-1 cells 
showed 23% CpG methylation in miR-184 regulatory region, 
in contrast to 90% CpG methylation in the HL-1Pkp2shRNA cells 
(Figure 5D). All the 15 identified CpGs showed greater hyper-
methylation in the HL-1Pkp2shRNA cells (Online Table IV).
To further validate the role of CpG methylation in miR-
184 expression, control HL-1 and HL-1PKP2-shRNA cells were 
treated with the nucleotide analogue 5-aza-2′-deoxycytidine 
for 5 days. Treatment with 5-aza-2′-deoxycytidine increased 
miR-184 levels in the control HL-1 and HL-1PKP2-shRNA cells. 
However, the magnitude of induction was greater in the HL-
1PKP2-shRNA, as compared with control HL-1 cells (2.4±0.2-fold 
versus 1.8±0.1-fold, respectively, N=3; P=0.004; Figure 5E). 
Nevertheless, despite increased expression of miR-184 on 
treatment with 5-aza-2′-deoxycytidine , its level in the HL-
1PKP2-shRNA cells remained reduced as compared with the con-
trol HL-1 cells, indicating a partial rescue.
To delineate the mechanism(s) responsible for hypermeth-
ylation of the CpG site in the 5-genomic region of miR-184, 
we analyzed recruitment of DNMT1 to the promoter region 
of miR-184 by ChIP assay. As shown in Figure 5F, genomic 
fragment of miR-184 was precipitated with an anti-DNMT1 
antibody, and the magnitude of the precipitated DNA was 
greater in HL-1PKP2-shRNA cells as compared with wild-type 
HL-1 cells (Figure 5G; 2.1±0.8–fold; P=0.0.17). To further 
substantiate the role of DNMT1 in suppression of miR-184 
levels, DNMT1 was targeted by recombinant lenti-viruses ex-
pressing an shRNA against Dnmt1 transcript. Knockdown of 
Dnmt1 by shRNA led to increased miR-184 levels (Figure 5H 
and 5I; 1.6±0.2-fold, N=4; P=0.03).
Integrated miRNA–mRNA Analysis
To delineate biological significance of downregulation of 
miR-184 in AC models and considering pleiotropic target-
ing of multiple mRNAs by a single miRNA, we performed 
a pairwise analysis of miR-184 and the differentially ex-
pressed mRNA targets in the HL-1PKP2-shRNA cells (Figure 6A 
and 6B). Only mRNA transcripts that met the target selection 
criteria were curated. Pairing of miR-184 and its known and 
predicted target mRNAs led to identification of 145 genes, 
whose expression levels were increased by 1.2-fold, and 40 
genes, whose expression levels were increased by at least 
2-fold (Figure 6C). Gene ontology over-representation analy-
sis (Figure 6D) identified mRNA clusters that were enriched 
for cellular death and survival (51 transcripts), growth and 
differentiation (51 transcripts), and cellular development (11 
transcripts). MiR-184 target genes involved specifically in cel-
lular differentiation were further curated, and their subcellular 
localization map is depicted in Figure 6E.
MiR-184 and Transcriptional Switch to 
Adipogenesis
Pathway analysis of paired miR-184 and its mRNA targets 
also identified networks of genes involved in lipid biosynthe-
sis (Figure 7A). Analysis of target transcripts in the networks 
showed upregulation of more than a dozen genes involved in 
lipid biosynthesis in the HL-1PKP2-shRNA as compared with the 
control cells (Figure 7B). Agpat1, Agpat3, Ncoa3, Ppargc1b, 
Dgat1, Dgat2, and Lpl, regulators of lipid biosynthesis, were 
upregulated by 2- to 4-fold (Figure 7B). Upregulation of a se-
lected number of genes in the lipid biosynthesis networks was 
also validated by qPCR (Figure 7C). Moreover, expression 
of the adipogenic transcription factor PPARG was increased, 
and fat droplets were accumulated in the HL-1Pkp2-shRNA cells 
(Figure 7D–7G). Knockdown of Pkp2 in MPCs also led to 
enhanced adipogenesis, as evidenced by increased number of 
cells expressing CEBPA (Figure 7H and 7J) and accumulating 
fat droplets (Figure 7I and 7K).
To determine whether the adipogenic genes identified in 
the pairwise miR-184-mRNA analysis were directly targeted 
by miR-184, the 3′ untranslated regions of the candidate genes 
were analyzed for the presence of miR-184 seed sequence. 
The 3′ untranslated regions of Agpat3, Ncoa3, Ppargc1b, and 
Dgat1 are conserved in mouse and human and were aligned 
with miR-184 seed sequence (Online Figure VI).
To validate the findings experimentally, HL-1 cells were 
transduced with recombinant lentiviruses expressing either an 
shRNA against miR-184 (Lenti:miR-184shRNA) or pre-miR-184 
to suppress or increase miR-184 levels, respectively (Online 
Figure V). Suppression and overexpression of miR-184 was 
confirmed by qPCR (Figure 7L). Knockdown of miR-184 
was associated with increased transcript levels of Agpat1 
and Agpat3 (Figure 7M). In contrast, overexpression of miR-
184 was associated with a modest but a significant decrease 
in the transcript levels of Agpat1 and Agpat 3 (Figure 7M). 
However, knockdown and overexpression of miR-184 did not 
affect Ncoa3 and Ppargc1b transcript levels, suggesting that 
mRNAs of these 2 genes were not directly targeted for degra-
dation by miR-184 (Figure 7M).
Effects of miR-184 on Adipogenesis
To further substantiate the causal role of miR-184 in adipogenic 
differentiation, expression of adipogenic markers and accu-
mulation of fat droplets were analyzed after suppression and 
overexpression of miR-184 in HL-1 cells and cardiac MPCs 
(Figure 8). Knockdown of miR-184 (Figure 8A) increased 
transcript levels of Agpat1 (24% increase, N=3; P=0.001), 
Agpat3 (20% increase, N=3; P=0.007), Pparg (2.1±0.6-fold, 
N=4; P=0.002), and Fabp4 (fatty acid–binding protein 4), a 
Figure 5 Continued.  precipitation and amplification of a 160-bp genomic region of miR-184 with an anti–DNA methyltransferase 1 
(DNMT1) antibody in a ChIP (chromatin immunoprecipitation) assay. G, Quantitative data from ChIP assay showing binding and fold 
increase in miR-184 5′ genomic region precipitated in ChIP assay (N=2). H and I, Rescue of miR-184 levels on knockdown of Dnmt1 
transcript by 4.5±1.4-fold (N=3; P=0.0001) and increased miR-184 levels (1.6±0.2-fold, N=4; P=0.03) on knockdown of Dnmt1 RNA. PKP2 
indicates plakophilin 2; and shRNA, short hairpin RNA.
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Figure 6. MiR-184:mRNA paired analysis. A, Volcano plot showing log2-fold change vs –log10 q values for differentially expressed 
mRNAs levels as quantified by RNA sequencing from HL-1 and HL-1Pkp2-shRNA cells. The dotted line shows a q value of <0.05. B, Volcano 
plot of differentially expressed miR-184 targets (red dots) superimposed on volcano plot of the differentially expressed transcripts 
showing miR-184 targets were upregulated in the HL-1Pkp2-shRNA cells. C, Heat plots of mRNA transcripts that were (Continued )  
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downstream target of PPARG (4.1±3.1-fold, N=4; P=0.02) in 
HL-1 cells (Figure 8B). Knockdown of miR-184 in cardiac 
MPCs (Figure 8C) also had similar effects on the transcript levels 
of the above adipogenic genes (Figure 8D). In contrast, overex-
pression of miR-184 had the opposite effects in both HL-1 cells 
and cardiac MPCs (Figure 8C and 8D). Immunofluorescence 
staining of HL-1 cells and cardiac MPCs for the expression of 
adipogenic transcription factors PPARG and CEBPA showed 
increased and decreased levels of the adipogenic transcription 
factors on knockdown and overexpression of miR-184, respec-
tively (Figure 8E–8H). Finally, suppression of expression of 
miR-184 was associated with increased accumulation of fat 
droplets in HL-1 cells and in cardiac MPCs, whereas overex-
pression had the opposite effects (Figure 8I–8L).
Rescue of Adipogenesis on Overexpression of miR-
184 in PKP2-Deficient HL-1 Cells
To rescue enhanced adipogenesis in the HL-1PKP2-shRNA cells, 
cells were transduced with the Lenti:pre-miR-184 construct 
to overexpress miR-184 (Figure 9A). Expression of miR-184 
was evaluated by qPCR, fluorescence-activated cell sorting of 
GFP+ cells, and quantification of miR-184 target transcript 
levels (Figure 9B–9D). As shown in Figure 9A, overexpres-
sion of miR-184 was associated with a significant reduction in 
the transcript levels of Pparg (25±10%, N=5; P=0.008), Fabp4 
(25±7%, N=5; P=0.02), Agpat1 (28±9%, N=5; P=0.0002), and 
Agpat3 (25±7%, N=5; P=0.0005). Likewise, the number of cells 
that contained fat droplets was decreased on overexpression of 
miR-184, as compared with nontransduced HL-1PKP2-shRNA cells 
(25±3% versus 17.6±4%, respectively, N=3200 cells per group 
per experiment; P=0.01; Figure 9E and 9F). Moreover, overex-
pression of miR-184 reduced the number of PPARG express-
ing HL-1Pkp2-shRNA cells (18.43±2.5% versus 14.37±1.5%, N=5; 
P=0.045; Figure 9G and 9H). Overexpression of miR-184 only 
attenuated and did not completely rescue enhanced adipogene-
sis in the PKP2-deficient cells because the number of cells with 
fat droplet remained greater in the transduced HL-1PKP2-shRNA  
cells as opposed to the nontransduced control HL-1 levels 
(25±3% versus 5.4±1.0%, respectively, N=5; P=0.001).
Discussion
The findings of the present study implicate miR-184, whose 
expression is progressively reduced in cardiac myocytes dur-
ing cardiac development, in the pathogenesis of enhanced 
adipogenesis in PKP2-deficient cells. Levels of miR-184 were 
markedly reduced in in vitro and in vivo models, including a 
new Pkp2-knockdown mouse model of AC. The mechanisms 
responsible for downregulation of miR-184 levels included 
suppression of the E2F1 pathway, which regulates miR-
184 expression on binding of E2F1 to its 5′ genomic region 
(Online Figure II). In addition, recruitment of DNMT1 leads 
to epigenetic silencing of the miR-184 locus on hypermeth-
ylation of the CpG-rich regions. Downregulation of miR-184 
levels was associated with upregulation of its target genes in-
volved in cell death, growth, proliferation, and differentiation. 
Notable among the perturbed pathways was upregulation of 
genes involved in lipid synthesis and enhanced adipogenesis. 
Overexpression and knockdown of miR-184 suppressed and 
enhanced adipogenesis, respectively, in HL-1 cells and cardiac 
MPCs. These findings collectively implicate miR-184 in the 
pathogenesis of excess adipogenesis in PKP2-deficient cells.
MicroRNA profiling and the mechanistic studies were per-
formed in the HL-1 cells, and selected findings, including the 
effects of miR-184 on adipogenesis, were confirmed in cardiac 
MPCs. The approach was in keeping with the higher expres-
sion levels of miR-184 in cardiac MPCs and murine embry-
onic hearts, as opposed to mature cardiac myocytes, which 
expressed miR-184 at low levels. Moreover, adult cardiac my-
ocytes are terminally differentiated cells with limited, if any, 
capacity for fate switch. In contrast, MPCs have the potential 
to differentiate to different lineages and been identified as a 
cell source of adipocytes in AC.36,44 Nevertheless, despite dem-
onstration of the role of MiR-184 in regulating cell fate in 2 
different cell types, the findings merit testing in in vivo models 
to determine contributions of miR-184 to adipogenesis in AC.
The study by no means is designed to identify all differen-
tially expressed miRNAs or mRNAs in the PKP2-deficient cells 
or mouse models of AC. The small sample size in the miRNA 
screening study is expected to lead to underdetection of differ-
entially expressed miRNAs as well as mRNAs (type II statisti-
cal error). Nevertheless, differential expressions of the candidate 
miRNAs, including miR-184, and mRNAs of interest were 
verified by qPCR in multiple sets of independent experiments. 
Differentially expressed miRs and mRNA were detected on 
comparing the PKP2-competent and PKP2-deficient cells but 
not PKP2-deficient HL-1 cells and cells transfected with a no-
target shRNA vector. The latter had no discernible effects on the 
transcript levels of selected miRs and mRNAs.
The current gene transfer and genetic engineering methods 
do not afford the opportunity to manipulate expression of miR-
184 in the subset of CD44pos/PDGFRApos/NKX2-5pos cardiac 
MPCs specifically and efficiently to assess in vivo phenotypic 
effects of manipulation of miR-184 levels. Moreover, it is also 
not feasible to isolate and further characterize the CD44pos/
PDGFRApos/NKX2-5pos cells in vitro. Consequently, the rel-
evance of the mechanistic studies, performed in cell culture 
systems to in vivo models and human AC, remains to be deter-
mined. Additional studies in in vivo models would be needed 
to delineate the role of miR-184 in the pathogenesis of AC.
Figure 6 Continued. upregulated by >1.3-fold in HL-1Pkp2-shRNA cells and predicted to be the targets of miR-184 by at least 2 different 
target prediction programs. D, Prediction of molecular and cellular functions regulated by the miR-184 targets as determined by the 
ingenuity pathway analysis (IPA). Top 3 functions are listed along with their corresponding P values and the number of affected genes.  
E, Gene network display from the IPA analysis of miR-184 targets showing the subcellular distribution and upregulation of miR-
184 targets involved in cell differentiation. ASXL2 indicates additional sex comb-like 2; CBFA2T2, core-binding factor runt domain 
alpha subunit 2; CD36, cell differentiation 36; CTNND1, catenin delta 1; CXADR, coxsackie virus and adenovirus receptor; FOS, FBJ 
osteosarcoma oncogene; IGFBP5, insulin growth factor binding protein 5; IL23A, interleukin 23, subunit alpha; NOTCH3, notch 3; 
OBSCN, obscurin; PKP2, plakophilin 2; PRNP, prion protein; PROX1, prospero homeobox 1; RAB27A, RAB27A, member RAS oncogene 
family; RASSF2, Ras association domain family member 2; RBL1, retinoblastoma-like 1; shRNA, short hairpin RNA; SLC8A1, solute 
carrier family 8 member A1; VDR, vitamin D receptor.
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Figure 7. Adipogenic genes as targets of miR-184. Protein functional association network, constructed using STRING online tool for 
paired analysis of miR-184 and its mRNA transcripts involved in triglyceride synthesis, including Agpat1, Agpat3, Ncoa3, and Ppargc1b. 
Genes directly targeted by miR-184 are highlighted as orange color. B, Heat plot constructed for paired analysis of miR-184 and its mRNA 
target networks involved in adipogenesis, which were upregulated in the HL-1Pkp2-shRNA cells. C, Confirmation of increased (Continued )  
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MiR-184, an evolutionary conserved intergenic single-
copy miR, was the most differentially expressed miRNA in 2 
independent lines of HL-1Pkp2-shRNA cells. PKP2 levels were re-
duced similarly between the 2 lines. Hence, a dose-dependent 
effect of PKP2 suppression on miR-184 levels could not be 
determined. The initial studies were performed in the HL-1 
cells, and the findings provided the impetus for generation and 
characterization of the Pkp2-deficient mice. Ab initio studies in 
cardiac MPCs are considered more pertinent and aligned with 
the working hypothesis. MicroRNA-184 was also downregu-
lated in cardiac myocytes isolated from the AC models and in 
2 independent mouse models of AC, including the new Nkx2.5-
Cre:Pkp2shRNA and the established Jup transgenic (Myh6:JupTr) 
mouse models.37 Whether mechanisms similar to those ob-
served in the PKP2-deficiency models are also responsible 
for downregulation of miR-184 in the heart in the Myh6:JupTr 
mice remain to be determined. Several other miRNAs were 
also dysregulated in the HL-1Pkp2-shRNA cells. However, among 
the most dysregulated miRNAs, expression of miR-184 was 
consistently suppressed in the HL-1 cells and mouse models. 
The magnitude of reduction was greater in the HL-1Pkp2-shRNA 
cells by ≈16-fold as compared with ≈2-fold reduction in the 
heart of the genetic mouse models. Milder reductions in the 
heart of transgenic models likely reflect cellular heterogeneity 
of the heart, expression of miR-184 only in a subset of cardiac 
cells, and downregulation of miR-184 levels in the adult heart. 
Knockdown of the Pkp2 gene under transcriptional regulation 
of the Nkx2.5 locus predominantly deletes Pkp2 in cardiac 
myocytes. NKX2-5 and PKP2, despite being predominantly 
expressed in the cardiac myocyte lineage, are also expressed 
in nonmyocyte cells in the heart, including a subset of cardiac 
MPCs, as shown in the present and previous studies.36 Such 
cellular heterogeneity in the expression of the key molecules 
relevant to the pathogenesis of AC may account for the dis-
crepancy in the magnitude of reductions of miR-184 levels in 
in vitro and in vivo models. Nevertheless, the findings are in 
agreement with the notion that only a subset of cardiac pro-
genitor cells differentiates to fibro-adipocytes in AC.2,36,45
In view of a more pronounced reduction of miR-184 levels 
in the HL-1Pkp2-shRNA cells, phenotypic effects and the mecha-
nistic studies were performed primarily in the HL-1 cells and 
subsequently in cardiac MPCs, surmising that the in vitro stud-
ies would provide a more sensitive platform for delineating the 
underpinning mechanisms than studies performed on the whole 
heart. These data are in keeping with our hypothesis that it is a 
subset of cardiac progenitor cells and not mature cardiac myo-
cytes that differentiate to adipocytes in AC.2,37,38,45 To strengthen 
the evidence for the observed effects, the biological effects of 
miR-184 were analyzed by complementary methods of overex-
pression and knockdown approaches in 2 independent cell types. 
Phenotypic consequences, including adipogenesis were detected 
by independent complementary methods, such as qPCR of the 
genes involved in lipid biosynthesis, immunofluorescence stain-
ing for adipogenic transcription factors, and Oil Red O staining 
of fat droplets. Collectively, the findings provide strong evidence 
for the role of miR-184 in the pathogenesis of AC.
In accord with targeting of multiple mRNAs by a single 
miR and, hence, phenotypic pleiotropy of each miRNA, miR-
184 is also implicated in various biological processes, notable 
among them is cell lineage specification.46–48 Suppression of 
miR-184 has been associated with reduced cellular prolif-
eration, clonal expansion, and differentiation of several pro-
genitor and precursor cells.46–48 Consistent with the role of 
miR-184 in cell fate determination, suppressed expression of 
miR-184, whether on shRNA-mediated targeting or indirectly 
on knockdown of PKP2, was associated with a transcriptional 
switch to adipogenesis and enhanced fat accumulation. At 
the molecular level, genes encoding AGPAT1 and AGPAT3, 
which convert lysophosphatidic acid into phosphatidic acid in 
lipid biosynthetic pathways, were identified as novel targets 
of miR-184.49 In accord with these findings, overexpression 
of AGPAT1 is shown to increase fatty acid uptake, triacylg-
lycerol production, and accumulation of fat droplets in the 
3T3-L1 and C2C12 cells.50 Likewise, Ncoa3 and Ppargc1b, 
which have prominent roles in adipogenic differentiation, 
along with several other adipogenic genes were upregulated 
on knockdown of PKP2. Transcriptionally, miR-184 targets 
Numbl, Sox17, Ncor2, and Akt2 are known to regulate cellular 
differentiation.47,51 In view of multiplicity of miRNA targets, 
the phenotype consequent to downregulation of miR-184 in 
HL-1Pkp2-shRNA cells or cardiac MPCs is the collective effects of 
changes in the expression levels of multiple targets and not a 
Figure 7 Continued. transcript levels of selected miR-184 targets involved in lipid metabolism (N=4). D, Immunofluorescence (IF) panels 
showing expression of nuclear peroxisome proliferator-activated receptor gamma (PPARG), an adipogenic transcription factor, in the 
control HL-1 and HL-1Pkp2-shRNA cells 14 days after induction of adipogenesis. E, Oil Red O (ORO)–stained panels showing increased lipid 
accumulation in the HL-1Pkp2-shRNA as compared with the control HL-1 cells 14 days after induction with an adipogenic medium. F and 
G, Corresponding quantitative data showing a 2.6±0.16-fold increase in the number of PPARG expressing HL-1Pkp2-shRNA and 4.7±0.4-
fold higher number of HL-1Pkp2-shRNA cells accumulating fat droplets, as compared with the control HL-1 cells (N=5, P<0.0001 and N=6, 
P<0.0001, respectively). H and I, CEBPA (CCAAT/enhancer binding protein alpha) expression and fat droplet accumulation in cardiac 
mesenchymal progenitor cells (MPCs) and MPCs knockdown for Pkp2 (MPCPkp2-shRNA) after 5 days of adipogenic induction. J, Quantitative 
data showing 1.7±0.13-fold increase in number of cells expressing adipogenic transcription factor CEBPA in the MPCPkp2-shRNA cells, 
as compared with control MPCs (N=3600 cells/group). K, Enhanced fat droplet accumulation (1.6±0.23-fold) in MPCPkp2-shRNA (N=3800 
cells/group) as compared with controls. L, Effects of knockdown and overexpression of miR-184 on selected target genes involved 
in adipogenesis. Transcript levels of Agpat1 and Agpat3 were increased by ≈2-fold in HL-1 cells transduced with Lenti:miR-184shRNA 
as compared nontransduced HL-1 cells (N=3 per group; P<0.05). Conversely, overexpression of miR-184 was associated with ≈25% 
decrease in the Agpat1 and Agpat3 mRNA levels (N=3; P=0.04), identifying these genes as the targets of miR-184. However, levels of 
Ncoa3 and Ppargc1b were not changed on overexpression or knockdown of miR-184. To avoid potential confounding effects of the 
vector backbones, experiments were repeated with the viral constructs that had identical viral backbones in the control NT-shRNA, 
knockdown, and overexpression groups. Similar results were obtained for changes in the transcript levels of selected adipogenic markers 
in cardiac MPCs (Online Figure VII). NT indicates no target; PKP2, plakophilin 2; and shRNA, short hairpin RNA.
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Figure 8. Effects of knockdown and overexpression of miR-184 on adipogenesis. A–D, Transcript levels of miR-184 and its targets 
showing knockdown (Lenti:miR-184shRNA) and overexpression (Lenti:pre-miR-184) of miR-184 in HL-1 cells and mesenchymal progenitor 
cells (MPCs) isolated from the heart. Levels normalized to nontransduced cells are presented as fold change. A, Transduction of HL-1 
cells with Lenti:miR-184shRNA construct, leading to increased transcript levels of several adipogenic genes (Pparg: 2.15±0.56, (Continued )  
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single target. The pleiotropic of effects hinders from manipu-
lation of a single miR-184 target as a means of phenotypic res-
cue. Consequently, the rescue experiments were performed on 
overexpression of miR-184 in the HL-1Pkp2-shRNA cells, which 
exhibit suppressed miR-184 levels. Collectively, the new find-
ings along with the existing data support a role of miR-184 
as a homeostatic balancer of proliferation and differentiation.
The effect size of miR-184 on the levels of its target transcripts 
were relatively modest, a finding that is consistent with the estab-
lished role of miRNAs as nudgers and tweakers of genome man-
agement.21 These subtle changes in gene expression and phenotype 
are inherent to miRNA regulatory networks that are not only de-
pendent on the changes in miRNA concentration but also depen-
dent on stoichiometric amounts of its target. Furthermore, miRs, 
in general, behave as a temporal agent to control targets or signal-
ing networks by setting a threshold of expression, thus, allowing 
or amplifying a signal in cohort with other transcription factors. 
Accordingly, in a complex phenotype such as AC, the phenotype 
is the consequence of a myriad of molecular changes that occur, 
including changes in the levels of multiple miRNA, as observed 
in the present study, each contributing to the phenotype, and none 
alone is a sole determinant.
MiR-184 is located in an imprinted locus on mouse chro-
mosome 9, and it is repressed on methylation of the CpG-rich 
sequences at its promoter region.47 In accord with the epigenetic 
silencing of the miR-184 locus, the upstream regulatory sites 
of miR-184 were hypermethylated in the HL-1Pkp2-shRNA cells. 
DNA methylation-dependent repression of miR-184 transcrip-
tion occurs by binding of methyl-CpG–binding protein 1 and 
methyl-CpG protein binding to the methylated regions.47,52 
Treatment with 5-aza-2′-deoxycytidine-D and suppression 
of DNMT1, as well as activation of the E2F1 transcription 
pathway, induced expression of miR-184 levels in HL-1 cells. 
Nevertheless, the magnitude of induction was insufficient to 
normalize the miR-184 levels in the HL-1Pkp2-shRNA cells. Failure 
to completely rescue suppressed miR-184 levels might reflect 
irreversible epigenetic silencing of this locus in the HL-1Pkp2-
shRNA
 cells. Moreover, several other mechanisms that were de-
lineated, particularly cell contact regulators, such as integrins, 
might contribute to downregulation of the miR-184 levels in 
the PKP2-deficient HL-1 cells, which were not studied. The 
mechanism(s) by which PKP2 impacts methylation of the miR-
184 locus is likely related to recruitment of DNMT1 by the RB1/
E2F1 complex to the 5′ genomic region of miR-184 (Online 
Figure II). The 2 delineated mechanisms, namely suppression 
of E2F1 and hypermethylation of 5′ genomic region of miR-
184, offer a unifying mechanism regulated by CCND1, which is 
markedly suppressed in the AC models.15 CCND1 is a regulator 
of CDK4/6, which target RB1 for inactivation on phosphory-
lation and, hence, gene expression through E2F1 transcription 
factor (Online Figure II). Consequently, reduced CCND1 levels 
and activation of RB1 might enhance recruitment of DNMT1 
to the genomic regions.43 Finally, given that PKP2 is known to 
localize to the nucleus in addition to the IDs,53,54 it is intriguing 
to postulate a role of the PKP2 in recruitment and assembly of 
DNMTs, directly or through interactions with other proteins in 
the promoter complex. As a whole, the findings suggest a pri-
mary role for increased CpG methylation, but also the involve-
ment of multiple mechanisms including suppression of E2F1 
pathway in downregulation of miR-184 levels in the HL-1Pkp2-
shRNA
 cells.
Activation of the Hippo pathway and reduced gene expression 
through its downstream effectors YAP-TEAD and the canonical 
Wnt signaling, which are impaired in the HL-1Pkp2-shRNA cells,15,16 
did not significantly influence miR-184 levels. Likewise, overex-
pression or knockdown of miR-184 did not affect transcriptional 
activities of these pathways. In contrast to a recent report indi-
cating that miR-184 suppresses the canonical Wnt signaling in 
retina,55 overexpression of miR-184 had no discernible effects on 
the transcript levels of selected canonical Wnt signaling targets in 
HL-1 cells. By-and-large, suppressed expression levels of miR-
184 were independent of the Hippo and canonical Wnt signaling 
pathway transcriptional activities in HL-1 cells.
In conclusion, the findings of the present study show patho-
genic downregulation of miR-184 in PKP2-deficient cells and 
mouse models of AC. The responsible mechanisms include sup-
pression of the E2F1 transcription factor pathway and epigen-
etic silencing of miR-184 genomic locus on CpG methylation. 
MiR-184 regulates adipogenesis in HL-1 cells and a subset of 
cardiac MPCs that express intercalated disc protein PKP2. The 
findings illustrate a pathogenic role for miR-184 in cellular pro-
liferation and enhanced adipogenesis PKP2 deficiency.
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Figure 9. Attenuation of adipogenesis on overexpression of miR-184 in the HL-1Pkp2-shRNA cells. A, Schematic of pre-miR-184 
expression construct showing expression regulation of miR by the CMV promoter and GFP by the EF1 promoter. B, Flow cytometry plot 
depicting GFP expressing in HL-1Pkp2-shRNA cells transduced with nontargeting control (NT-shRNA2) or Lenti:pre-miR-184 viruses.  
C, Quantitative polymerase chain reaction (qPCR) analysis of miR-184 levels in HL-1Pkp2-shRNA cells transduced with Lenti:pre-miR-184 
(N=3, P<0.0001). D, Reduced mRNA levels of Pparg (27±10%), Fabp4 (25±12%), Agpat1 (26±13%), and Agpat3 (25±9%) in (Continued )  
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What Is Known?
•	 Arrhythmogenic cardiomyopathy (AC) is a genetic disease that clini-
cally manifests with ventricular arrhythmias, heart failure, and sudden 
cardiac death.
•	 Pathological hallmark of AC is replacement of cardiac myocytes by 
fibro-adipocytes, particularly in the right ventricle.
•	 Mutations in genes encoding desmosome (intercalated disk) proteins 
are identified in approximately half of the families with AC.
•	 PKP2, encoding plakophilin 2 (PKP2), is the most common causal gene 
for AC.
What New Information Does This Article Contribute?
•	 Knockdown of Pkp2 in HL-1 cells led to dysregulation of 59 microRNAs.
•	 MicroRNA-184 was the most downregulated, whereas the miR-200 
family was the most upregulated microRNAs in the Pkp2-knockdown 
HL-1 cells.
•	 Knock down of Pkp2 in the mouse heart was also associated with 
downregulation of miR-184.
•	 Expression of miR-184 was progressively downregulated during cardiac 
development, being the highest in early embryonic heart and in cardiac 
mesenchymal progenitor cells and lowest in adult cardiac myocytes.
•	 Knock down of PKP2 led to epigenetic silencing of miR-184 through 
increased recruitment of DNA methyltransferase 1 and hypermethylation 
of the CpG sites at its 5′ genomic region, as well as suppression of the 
E2F1 transcription factor, which regulated miR-184 on direct binding 
to the 5′ genomic region.
•	 Suppression of miR-184 enhanced and its activation attenuated adipo-
genesis through direct targeting of adipogenic genes in mesenchymal 
progenitor cells and HL-1 cells.
MicroRNA-184 is a developmentally regulated miR, whose ex-
pression is highest in the embryonic heart and cardiac mesen-
chymal progenitor cells and lowest in adult cardiac myocytes. 
Developmental downregulation of miR-184 is enhanced in PKP2-
deficient myocytes. Expression of miR-184 is regulated by the 
E2F1 transcription factor and CpG hypermethylation at its 5′ ge-
nomic region, which are suppressed and enhanced, respectively, 
in PKP2 deficiency. MiR-184 regulates proliferation and adipogen-
esis in HL-1 cells and cardiac mesenchymal progenitor cells. The 
findings suggest a role for miR-184 in the molecular pathogenesis 
of adipogenesis in PKP2 deficiency. The findings set the stage for 
additional studies in in vivo models and humans with AC.
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MATERIAL AND METHODS  
The investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health. The Animal Care and Use Committee and 
Review Board as well as Biological Safety Committee of the University of Texas Health Science 
Center-Houston approved the studies.  
Recombinant viruses: Recombinant lentiviruses were generated as published 1. In 
brief, the shRNAs were cloned into a miR-Zip vector downstream to an H1 promoter for miRNA 
knockdown and a CMV7 promoter for miRNA overexpression studies. Two shRNAs with no 
known targeting sequence in mammalian genome were used as controls (NT-shRNA1 as a 
control for knock down and NT-shRNA 2 for overexpression studies). The vector also expresses 
a Green Fluorescence Protein cloned form copepod Pontellina plumata (copGFP, henceforth 
GFP) reporter to facilitate identification of the transfected cells (modified from System 
Biosciences, cat # MZIP-184-PA-1, www.systembio.com). MiR-184 overexpression construct 
was generated by inserting a 500bp genomic fragment of miR-184 (250bp upstream and 250bp 
downstream to mature transcript) into the miR-Express vector (modified from System 
Biosciences, cat#MMIR-200b-PA-1 from System Biosciences). DNMT1, DNMT3A, and 
DNMT3B proteins where knocked down using commercially available lentiviral shRNA 
constructs (Mission shRNAs, Sigma-Aldrich). Sequence data for the shRNAs are presented in 
Online Table I. For virus production the plasmids were transfected into 293T cells using X-
tremeGENE9 DNA transfection reagent (Roche Life Science, Product # 06365787001, 
www.roche.com). The infectious lentiviral particles were harvested at 48h and 72h post 
transfection, cleared by precipitation of cell debris and then filtered through 0.45-µm-pore 
cellulose acetate filters (VWR International, cat # 28145-479). To transduce the HL-1 cells (a 
mouse atrial cardiac myocyte AT-1 tumor lineage cell line 2), cells were grown to 70-90% 
confluence in the Claycomb medium (Sigma, www.sigmaaldrich.com, cat # 51800C), infected 
with the recombinant viruses for 48h, and then were cultured in the virus free Claycomb medium 
	 3	
for another 24h. Transduction efficiency was determined by detection of the GFP signal under 
fluorescence microscopy or by FACS analysis. A pre-packaged ready-to-use Adenoviral 
construct expressing CCND1 was used to over express CCND1 (Vector Biolabs, 
http://www.vectorbiolabs.com/Recombinant-Adenovirus/1517/Ad-Cyclin-D1/Cyclin-D1, Catalog: 
1517).  
Suppression of expression of PKP2 in the HL-1 cells: The HL-1 cell lines deficient in 
PKP2 (HL-1Pkp2-shRNA) were generated as published 1. In brief, HL-1 cells were cultured in the 
Claycomb Medium on tissue culture plates coated with gelatin and fibronectin. Cells were 
transduced with the recombinant lentiviruses expressing an shRNA that targets the Pkp2 mRNA 
(Lenti:Pkp2shRNA). Two HL-1PKP2-shRNA lines were established using two independent shRNAs 
(TRCN000012335, targeting position 251-271，and TRCN0000123351, targeting position 1126-
46) by culturing the cells on a growth medium supplemented with 50 ug/ml puromycin for 2 
weeks. Independent shRNAs that had no potential target sites in the mammalian genome 
(Lenti:non-targetshRNA abbreviated as NT-shRNAs) were used as controls in these experiments 
(Sigma, www.sigmaaldrich.com, cat. # SHC016). Knockdown of Pkp2 mRNA and PKP2 protein 
levels were detected by qPCR and immunoblotting (IB), respectively.  
Isolation of cardiac myocytes: Mice were anesthetized by intra-peritoneal (I.P.) 
injection of pentobarbital at 62 mg/Kg. An aliquot of 200U of heparin was injected IP to prevent 
clot formation. The heart was removed and placed in a Ca2+ free perfusion buffer [120 mM NaCl, 
15 mM KCl, 0.6 mM KH2PO4, 0.6 mM Na2HPO4, 1.2 mM MgSO4 7H2O, 30 mM Taurine, 4.6 
mM NaHCO3, 10 mM HEPES, 10 mM 2,3-Butanedione monoxime (BDM), and 5.5 mM Glucose; 
pH 7.0]. The heart was perfused through ascending aorta with the perfusion buffer for 2 minutes 
at a constant rate of 4 mL/min. Then the heart was perfused with a digestion buffer containing 
624 U/mL of collagenase II solution (Worthington, Lakewood, NJ) for 2 minutes. Following the 
above 10 ul of 100 mM CaCl2 was added to the digestion buffer until complete digestion. The 
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heart was then cut into small pieces in the presence of the digestion buffer and cells were 
dissociated by gentle pipetting. Upon complete dissociation of the cells, a stop buffer (10% calf 
serum and 12.5 µM CaCl2 in the perfusion buffer) was added, cells were passed through a 100 
µm nylon mesh, and transferred to a 15 ml polypropylene conical tube. Myocytes were let to 
sediment by gravity in the presence of 200 mM ATP and centrifugation at 20 g for 3 min. The 
precipitated cells were re-introduced to calcium upon incubation in the stop buffer containing 
200 µM, 500 µM, 1 mM and 1.5 mM of CaCl2 sequentially. The final isolate was resuspended in 
a plating media (MEM media, 1% penicillin-streptomyocin, 10% Calf serum, 10 mM BDM, and 2 
mM ATP) in culture dishes or cover glasses coated with laminin in a 2% CO2 incubator at 37 oC.  
Isolation of mesenchymal progenitor Cells (MPCs): CD44 and PDGFRA (CD140A) 
enriched cardiac MPCs were isolated from adult murine hearts upon treatment of myocardial 
tissues with liberase (Liberase TM Research Grade, Roche, CA, 05401119001) and sorting of 
the dissociated non-myocyte cell fraction against anti CD44  (eBioscience, San Diego, CA 17-
0441-81) anti PDGFRA (eBioscience, San Diego, CA 92121) antibodies. Cells were also sorted 
against hematopoietic lineage antibodies cocktail to exclude such cells (BD Pharmingen, BD 
Horizon™ V450 Mouse Lineage Antibody Cocktail, with Isotype Control, cat #561301) 3-5. 
Isolated Linneg:CD44pos:PDGFRApos cells were plated at the density of 2.5 x 104/cm2 in a growth 
medium (DMEM/F12 media supplemented with 1XB27) also containing mouse basic Fibroblast 
Growth Factor (bFGF) at 10 ng/mL concentration (R&D, Minneapolis, MN; cat #3139-FB), 1000 
U/mL of mouse Leukemia Inhibitory Factor (mLIF) (Millipore; cat # ESG1106) and 1% Antibiotic-
Antimycotic solution. Cells were incubated at 37 °C in a 5% CO2 humidified incubator.  
PKP2 was knocked down in the MPCs using  the same shRNAs  that were used to 
generate HL-1PKP2-shRNA cells (TRCN000012335, targeting position 251-271 ， and 
TRCN0000123351, targeting position 1126-46). An shRNA that has no potential target site in 
the mammalian genome (Lenti:non-targetshRNA abbreviated as NT-shRNA) was used as a control 
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(Sigma, www.sigmaaldrich.com, cat. # SHC016). Knockdown of Pkp2 mRNA were detected by 
qPCR. To avoid potential confounding effects resulting from different viral backbones among the 
groups, transduction studies were performed with vectors with identical backbones or the 
experiments were repeated using control viral vectors with a backbone identical to that used in 
the knock down and over-expression constructs.  
Mouse models of AC: Myh6:JupTr mice have been published 6-8. To knock down the 
Pkp2 gene in the heart, an shRNA targeting the Pkp2 mRNA (position 1154-1174) was cloned 
into the U6-LoxP-Neo vector 9, 10. The construct contains a LoxP neo cassette downstream to 
the U6 promoter and is inactive unless the LoxP-Neo cassette is removed upon expression of 
the Cre recombinase. Nkx2-5:Cre deleter mice was used to conditionally express the Pkp2shRNA 
and suppress expression of the Pkp2 in the cardiogenic lineage 11. 
MicroRNA expression profiling: Expression profile of miRNAs was determined using 
TaqMan low-density (TLDA) microfluidic cards (Rodent miRNA v3.0 Card A and Card B Applied 
Biosystems). The panels contain a total of 750 mature miRNAs of which 641 are annotated and 
curated in the mouse genome. The panel also contains the mouse small nucleolar RNAs 
(MammU6), for data normalization and relative quantification. Each panel includes four sets of 
control assays, three candidate endogenous control assays and one negative control assay. 
Among the four control assays, MammU6 is spotted in triplicate in each card and provides a 
more reliable indicator for normalization of the miRNA levels.  In brief, 500 ng aliquots of RNA 
isolated from the HL-1 and HL-1Pkp2-shRNA cells from two independent experiments were reverse-
transcribed using Megaplex Primer Pools (Rodent Pools Set v3.0, cat#4444766). MiRNA 
cDNAs were loaded into the wells and subjected to qPCR on a 7900HT system per the 
manufacturer’s protocol (Life Biotechnology, www.lifetechnologies.com). Raw TLDA data files 
were quality controlled and miRNA with Ct values greater than 36 were excluded from further 
analysis. Heat plots for differentially expressed miRNAs were plotted using Gene-E 
(http://www.broadinstitute.org/cancer/software/GENE-E/index.html). 
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In situ hybridization: In situ hybridization was performed at Baylor College of Medicine 
Core laboratory per a published protocol 12. In brief, to detect expression for miR-184, thin 
myocardial sections were embedded in optimal cutting temperature (OCT) compound (Sakura 
Finetek Inc, Torrance, CA). Tissue sections were then acetylated for 10 min in freshly prepared 
TEA buffer (4.63 g triethanolamine HCl, 0.56 ml 10N NaOH and DEPC treated H2O up to 250 
ml) and washed in PBS for three minutes. The slides were then pre-hybridized with the 
hybridization solution (4°C Formamide 100%, SSC 20x, Denhart’s reagent, Yeast tRNA at 
10mg/ml, Herring sperm DNA at 500 µg/ml, EDTA at 2.5 mM, Tween-20 at 10%, CHAPS at 
0.25% and H2O). Slides were then incubated for 24 h at 65°C and wash 3 times each for 20 
minutes in 0.2x SSC at 65°C, blocked in 1x PBS, 0.1% Triton X-100, and 1% blocking reagent 
for 1 hour at RT. Slides were then hybridized with aliquots of 15-60 nM of 5' and 3' DIG-labeled 
miRCURY LNA™ Detection probe (Exiqon, Catalog Product no.: 18072-15) in the hybridization 
buffer. Following hybridization slides were washed PBS and 0.1% Triton X-100 for 20 min, 
placed in an amplification buffer, and mount in Vectastain with DAPI, seal with nail varnish. 
ChIP Assays: ChIP assays were performed using a ChIP-IT High Sensitivity kit (Active 
Motif, Catalog number: 53040). Briefly, HL-1 and HL-1Pkp2-shRNA cells were cross-linked in 1% 
formaldehyde for 10 minutes. DNA-protein cross-linking was stopped by incubation the samples 
in 0.125 M glycine. Cells were then washed, and recovered for chromatin preparation and lysis 
using ACTIVE MOTIF ChIP-IT High Sensitivity Kit (Catalog # 53040). Lysates were sonicated 
using a cell disruptor (Fisher Scientific Model 500 Sonic Dismembrator) for 10 cycles of 30 sec 
ON and 60 sec OFF yielding a genomic DNA fragments of ~200-1000 bp size. Chromatin 
immunoprecipitation and washing where performed as described in the manufactures protocol. 
Aliquots of 5 ug of anti E2F1 and anti DNMT1 antibodies where used in the ChIP assays (Online 
Table I). Quantitative PCR analysis of ChIP assays was performed using 2 µL of the ChIP DNA 
and SYBR green master mix. Enrichment of binding on the miR-184 promoter was presented, 
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as normalized to Input amount and relative to a control IgG group. All primers sequences are 
listed in Online Table I.  
IB: IB was performed per the conventional methods 1. In brief, total cellular protein was 
extracted using a RIPA lysis buffer in the presence of protease and phosphatase inhibitors. 
Protein concentration was measured using the Bio-Rad DC Protein Assay Kit (Bio-Rad 
Laboratories, www.bio-rad.com, cat # 5000111). Following denaturation in a 4X Laemmli buffer 
at 95 °C for 5min, extracts were subjected to electrophoresis on the SDS/PAGE gel and 
transferred to a nitrocellulose membrane. The membranes, after blocking in 5% milk, were 
incubated with the primary antibody overnight (primary and secondary antibody list is available 
in Online Table I), followed by incubating with the corresponding HRP conjugated secondary 
antibody. Signal was detected by chemiluminescence. 
Immunofluorescence staining:  Cells were fixed in 4% paraformaldehyde for 15 
minutes, washed 3X for 5 minutes each, and blocked in 5% donkey serum in PBS containing 
0.3% Triton X-100 (0.03% Triton X-100 for PKP2 staining) for 60 minutes at room temperature. 
After blocking, cells were incubated with the primary antibody (Online Table I) with 1% BSA and 
0.3% Triton X-100 (0.03% for PKP2 staining) overnight at 4 °C. After 3 washes, cells were 
incubated with corresponding secondary antibody in 1% BSA and 0.3% Triton X-100 for 1 hour 
at room temperature. Cells were then washed for 3 times and stained with DAPI. Slides were 
analyzed using Axioplan Fluorescence Microscope (Zeiss). Cells showing fluorescence signals 
beyond the levels detected for the IgG isotype of the corresponding antibody were considered 
as stained positive for that specific antigen.   
Quantitative PCR (qPCR):  Total RNA (including miRNA) was extracted using 
miRNeasy kit (Qiagen, www.quiagen.com, cat # 271004) and cDNA was synthesized using 
either a high-capacity cDNA Reverse Transcription Kit (Life technology, cat # 4368814) for 
mRNA conversion or a MicroRNA Reverse Transcription Kit (Life technology, cat # 4366596) for 
miRNA conversion. Quantitative PCR was performed using specific TaqMan gene express 
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assays and TaqMan MicroRNA assay. Gapdh and snoRNA202 expression levels were 
measured for normalization for mRNA and miRNA levels, respectively. ΔΔCt (2DDCt) method was 
used to calculate the normalized gene expression values. 
Transcript levels of snoRNA202 showed minimum variability in the HL-1 and mouse 
heart RNA samples. The mean Ct ± SD value of snoRNA202 transcript levels in 50 experiments 
(150 triplicates) in the HL-1 cells was 23.13 ± 0.62. Likewise, the mean Ct ± SD value of 
snoRNA-202 transcript levels in 25 experiments in the mouse heart samples was 21.80 ± 0.37. 
These data show a modest variability in the snoRNA202 levels in the HL-1 cells and myocardial 
samples, which bode confidence in the use of snoRNA292 levels in normalization of the miRNA 
levels.  
Raw expression values, presented as ΔΔCt, were used for statistical analysis. For 
graphical representation the data in the experimental groups were normalized to the average 
expression value in the control samples and present as relative fold change to the control 
samples. The later was normalized and set at 1. 
 MicroRNA targets and miRNA-mRNA pairing: Global gene expression patterns in the 
HL-1 and HL-1Pkp2-shRNA cells, determined by whole transcriptome sequencing (RNA-Seq), were 
compared to identify differentially expressed mRNA transcripts and are published 1. Predicted 
miR-184 targets were identified using miRWalk online software (www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/). Genes that were identified as targets in at least 2 different 
databases were included in the subsequent analysis. MiRNA-mRNA pairing was carried out 
using the Ingenuity Pathway Analysis (IPA) software (www.ingenuity.com). Pairing of miRNA-
mRNA for all differentially expressed miRNAs was performed using the following criteria: First, 
all putative target of a given miRNA were identified using the miRwalk software. Targets that 
were identified by at least 2 programs and had a seed length of 6 nucleotides or longer were 
included for further analyses. The heat maps of the RNA-seq data were generated based on 
differentially expressed transcripts that are statistically significant at a stringent false discovery 
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rate of less than 5% (q value <0.05), had a FPKM value of at least 1 in one of the samples, and 
showed a reciprocal expression to that of the corresponding miRNAs. Finally, target gene 
expression cutoff was set at 1.2 fold expression and a q value of 0.05. Based on these 
benchmarks potential miR-184 targets where identified and included them in subsequent 
analysis. To examine the potential biological significance of paired changes, gene ontology 
over-representation analysis, upstream regulator and canonical pathway analysis was 
performed using IPA. 
Heat plot and Gene network analysis: A heat map depicting miRNA expression levels 
was generated using the expression values obtained from the 2ΔΔCt method and plotted for the 
expression value for each miRNAs. Each value was normalized to the mean value of the 
transcript in that row. Heat plots for mRNAs where generated from the raw FPKM values 
obtained by RNA-seq experiment. Heat plot were generated using the GENE-E software 
(http://www.broadinstitute.org/cancer/software/GENE-E). 
A protein functional association network for miR-184 targets involved in adipogenesis, 
Agpat1, Agat3, Ncoa1, and Ppargc1b, was constructed using the STRING online tool. The 
medium confidence score for interaction was set at 0.4 and the option for all active prediction 
method was included. Direct interactions are depicted as colored nodes in the Network. Gene 
that are identified as members of the network and were found to be up-regulated in the HL-1Pkp2-
shRNA cells in RNA-seq data were further validated to build a miR-184 target network for 
adipogenesis. 
Proliferation, viability and apoptosis:  Cells were plated in triplicate in 96-well plate at 
a density of 5x103 to 10x103 cells per well. Cell viability was determined by CellTiter-Blue Cell 
Viability Assay (Promega Corporation, www.promega.com, cat # G8080) every 24h for 72 
hours. At each time point, 20µl of CellTiter-Blue reagent was added to the cells, and incubated 
at the culture conditions for 1 hour followed by measurement of the fluorescence signal at 
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560/590nm wavelength. Cell growth curve was generated using the corresponding fluorescence 
value at each time point. Cell doubling time was calculated using an exponential growth 
equation based on the fluorescence value at each time point. 
Adipogenesis:  Induction and quantification of adipogenesis was as described 1. In 
brief, ~5 x104 HL-1 cells were plated on gelatin and fibronectin coated cover glass, and treated 
with an adipogenesis induction medium [HL-1 media supplemented with 1uM dexamethasone 
(Sigma, cat # D8893), 0.5mM 3-isobutyl-1-methylxanthine (Sigma, cat # I7018) and 10ug/mL 
insulin (Cayman Chemical, cat # 10008979)] for 14 days. Quantitative PCR and IB were used to 
quantify transcript and protein levels of selected genes that regulate adipogenesis, respectively.  
To induce adipogenesis in MSC, cells were plated at a density of ~5 x104  cells on 
gelatin-coated plates in DMEM/F12 media supplemented with 1XB27 and 1uM dexamethasone, 
0.5mM 3-isobutyl-1-methylxanthine and 10ug/mL insulin for 5 to 14 days.  
Accumulation of fat droplets was assessed by Oil Red O staining, and the number of 
cells stained positive for Oil Red O was determined in at least 15 to 20 randomly selected high 
(100X) magnification fields and in 3-5 independent experiments. PPARG staining (for HL-1 cells) 
and CEBPA staining for (MSCs) was performed as described in the IF section and CEBPA or 
PPARG+ cells where counted from 10-15 randomly selected field (200 to 600 cells /group) from 
3 independent experiments.  
Activation and suppression of selected signaling pathways: To delineate the 
mechanism of suppression of miR-184 in AC models, we determined the effect of activation and 
suppression of the RB1/E2F signaling pathway on miR-184 levels. To activate the E2F1 
pathway, suppressed in the HL-1Pkp2-shRNA cells, serum starved HL-1 cells, plated at a density of 
2 - 4 × 105 cells, were transduced with recombinant adenoviruses expressing CCND1 at a MOI 
of 10 infectious particle/cell. Twelve hours post transduction, serum free media was switched to 
complete Claycomb media with serum and cells were cultured for another 48 h. Control 
adenoviruses (Ad5-CMV vector alone) were included as controls. Retinoblastoma 1 (RB1) was 
	 11	
knocked down using a commercially available siRNA construct (ON-TARGET plus Rb1 siRNA 
construct, Dharmacon: J-047474-08-0002). Cells were transfected with 10 nM of Rb1 or control 
siRNAs using RNAiMax reagent (Thermo Fisher Scientific, Catalog: 13778030). DNMT1, 
DNMT3A, and DNMT3B were knocked down using recombinant lentiviruses expressing 
respective shRNAs, as described above. 
The Hippo, and canonical Wnt signaling pathways were analyzed for their effects on 
expression levels of miR-184 1, 6. To activate the canonical Wnt signaling pathway, cells were 
treated with Wnt-3A (R&D Systems, www.rndsystems.com, cat # 1324-WN) at three 
concentrations of 40, 80, and 120 ng/mL for 24h. To suppress the canonical Wnt signaling 
pathway, HL-1 cells were transduced with recombinant lentiviruses expressing shRNA against 
Tcf7l2 mRNA (Lenti:Tcf7l2shRNA), a canonical Wnt effector. Reduced levels of TCF7L2 were 
confirmed in the protein extracts of HL-1 cells by IB. Activation or suppression of the canonical 
Wnt signaling pathway was also confirmed by quantifying mRNA levels of its well-established 
targets, namely, Axin2 and Ccnd1 and a Tcf7l2-luciferase reporter assay.  
To activate gene expression through the Hippo pathway, HL-1 cells, cultured in serum 
free medium, were treated with 1uM of 1-Oleoyl lysophophatidic acid (LPA, Cayman Chemical, 
www.caymanchem.com, cat # 62215) for 1, 2 and 4h. To suppress gene expression through the 
Hippo pathway, HL-1 cells were transduced with the recombinant lentiviruses expressing an 
shRNA against Yap mRNA (Lenti:YapshRNA). Activation or suppression of the Hippo signaling 
pathway was determined by quantification of YAP protein levels, transcript levels of the target 
genes Ctgf and Cry61 by qPCR, and by a TEAD-luciferase reporter assay. 
DNA methylation assay: To determine whether suppression of miR-184 was a 
consequence of DNA methylation dependent epigenetic silencing of the locus, genomic 
sequence upstream of the pre-miR-184 start site for the presence of CpG rich regions. Using 
EMBOSS Cpgplot (web based tool for CpG Island prediction,) 15 CpG sites with 
observed/expected ratio of > 0.60, located 500-800 bp upstream to the pre-miRNA start site, 
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were identified. This region was used for DNA methylation analysis by bisulfite conversion, 
cloning and sequencing of individual clones. Genomic DNA was extracted from the HL-1 and Hl-
1Pkp2-shRNA cells using the DNeasy Blood & Tissue Kit (Qiagen, Catalog# 69504) per the 
manufacturer’s protocol. Genomic DNA (2ug) from each sample was treated for bisulfite 
conversion using EpiTect Bisulfite Kits (Qiagen, Catalog# 59104,) according to the 
manufacturer’s recommendations. Aliquots of 50-100 ng of bisulfite converted DNA was PCR 
amplified using primers specific to the miR-184 upstream region (Online Table I). PCR products 
were cloned into pCR 2.1 vector using a TA cloning strategy. After transformation, positive 
colonies were screened by colony PCR. Plasmids from the positive colonies were isolated and 
then sequenced. Methylation of CpG sites was analyzed using QUMA online tool 
(http://quma.cdb.riken.jp/).  
Statistics: Data were presented as mean ± SD. Differences in the continuous variables 
between the two groups were compared by t-test or Mann-Whitney U test and among multiple 
groups by one-way ANOVA. Whenever applicable multiple groups Bonferroni corrected p values 
for pairwise comparisons were presented. Differences among the categorical values were 
compared by Kruskall-Wallis test. Statistical analyses were performed using Graph pad Prism or 
STATA 10.1 software. Statistical significance for methylation at each CpG sites was calculated 
by Fisher exact test (QUMA online tool).  
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ONLINE FIGURE LEGENDS 
 
Online Figure I. Development downregulation of miR-184 in isolated cardiac 
myocytes and its differential expression in the PKP2-deficient myocytes:  
A. Levels of Pkp2 mRNA were consistently lower in P3, P21 and P90 myocytes isolated 
from the Nkx-2.5-Cre:Pkp2shRNA mouse hearts than the wild type myocytes, indicating 
effective knock down of Pkp2 (N=3 to 4 per group). B) Expression of miR-184 levels in 
P3, P21, and P90 cardiac myocytes isolated from wild type and Nkx-2.5-Cre:Pkp2shRNA 
mice. As shown, miR-184 levels were suppressed in cardiac myocytes isolated from the 
Nkx-2.5-Cre:Pkp2shRNA mice in all three stages of development, as compared to 
myocytes isolated from the wild type mice (N=3 to 4 per group)   
 
Online Figure II. Hypothesis tested to explain the mechanisms responsible for 
suppression of miR-184 in AC: Deficiency of PKP2 protein at the intercalated discs 
(and desmosomes) impairs mechanical integrity of the myocytes and activates 
mechanosenstive transduction pathways, such the Hippo, canonical Wnt and integrin 
signaling pathways. Perturbed mechanosensitive signaling pathways result in 
suppression of cyclin D1 (CCND1) expression, which is a co-activator of cyclin-
dependent kinases (CDK) 4 and 6. Reduced CDK4/6 activity leads to 
hypophosphorylation and activation of retinoblastoma protein (RB1), which inhibits the 
E2F transcription factors and the ensuing suppressed gene expression through E2F1 
transcription factor. The RB1/E2F1 complex is known to recruit DNMT1 to the genomic 
regions, which then leads to hypermethylation of the CpG rich sites and further 
suppression of gene expression. 
 
Online Figure III. Effects of the Hippo pathway on miR-184 expression: A and B) 
Immunofluorescence panels and the corresponding quantitative data showing 
expression of the Hippo effector protein YAP in the control cells and cells treated with 
LPA for 1 hour. Treatment with LPA led to increased nuclear localization of YAP (N=2, 
68±2% vs. 87±0.5, p=0.0039). C) TEAD–luciferase reporter assay showing activation of 
YAP/TEAD –mediated transcription in HL-1 cells treated with 1uM of LPA for 3 different 
time points (N=3, corrected p values for pairwise comparisons to control cells are 
shown). D) Quantification of transcript levels of selected YAP/TEAD targets showing 
induction of Ctgf and Cyr61 (maximum induction of 2.87±0.38 and 6.13±1.73 -fold, 
respectively, N=3, p<0.001) after treatment with 1uM LPA at 3 different time points. E) 
Quantitative PCR data of miR-184 levels in the experimental groups showing no effect of 
activation of YAP/TEAD pathway on miR-184 expression. F) Transcript levels of 
YAP/TEAD targets in the HL-1Pkp2:shRNA cells treated with 1uM of LPA and analyzed at 3 
time points after treatment. Ctgf and Cyr61 transcripts show a maximum induction of 
2.34±0.72 and 5.06±3.01 –fold, respectively (N=3, p<0.001). G) Transcript levels of miR-
184 showing no change upon activation of the YAP/TEAD pathway. H) Immunoblot 
showing knock down of YAP (~ by about 40%) upon transduction of HL-1 cells with 
Lenti:YapshRNA. I) Transcript levels of YAP/TEAD targets Ctgf and Cyr61 showing 
reduced levels (31±0.1% and 40±0.1%, respectively, N=3, p<0.01). J) Transcript levels 
of miR-184 showing no change upon suppression of expression of YAP in the HL-1 
cells. 
 
Online Figure IV: Effects of canonical Wnt on miR-184 expression A) Dose-
dependent activation of the canonical Wnt signaling pathway upon treatment with an 
increasing dose of recombinant Wnt-3A protein (40-120ng/ml) in HL-1 cells as measured 
by the TCF7L2–luciferase reporter assay (N=3, p<0.05 as compared to untreated control 
HL-1 cells). B) Increased mRNA levels of selected canonical Wnt target genes Axin2 
(maximum induction of 3.84±1.40 –fold, N=4, p<0.05) and Ccnd1 (maximum induction of 
2.32±0.76 –fold, N=4, p<0.05) in a dose dependent manner upon treatment of HL-1 cells 
with Wnt-3A. C) Transcript levels of miR-184 in the same set of experiments as in III-B 
showing no change. D) Activation of the canonical Wnt pathway in the HL-1Pkp2-shRNA cells 
as measured by TCF7L2-luciferase reporter assay  (N=3, p<0.05 as compared to 
untreated control HL-1 cells. E) A dose-dependent increase in the transcript levels of the 
canonical Wnt targets Ccnd1 (maximum induction of 3.24 ±1.18 -fold, N=5, p<0.05) and 
Axin2 (maximum induction of 4.39±0.75  -fold, N= 5, p<0.01). F) Transcript levels of 
miR-184 showing a modest dose-dependent increase upon activation of canonical Wnt 
signaling (N=5, p=0.06 as compared to untreated HL-1Pkp2-shRNA cells). G) Immunoblot 
showing reduced levels of the canonical Wnt effector TCF7L2 in HL-1 cells transduced 
with Lenti:Tcf7l2shRNA. H) Data showing reduced transcript levels of Axin2 and Ccnd1 
upon transduction of HL-1 cells with Lenti:Tcf7l2shRNA. I) Transcript levels of miR-184 as 
detected by qPCR showing no change upon suppression of TCF7L2 (N=3, p>0.05). 
 
Online Figure V: Effects of miR-184 on the Canonical Wnt and Hippo signaling 
activities: Panel A shows schematic presentation of Lenti:miR-184shRNA (knock down) 
and Lenti:Non-targetshRNA (NT-shRNA1). The miR-184-shRNA construct expresses an 
shRNA hairpin from a RNA polymerase III H1 promoter. The vector also expresses 
copGFP (variant of EGFP, henceforth GFP). This gene serves as a fluorescent reporter 
for the transfected or transduced cells. Panel B represents Lenti-Pre-miR-184 over-
expression construct. CMV promoter drives Pre-miR-184 expression in the construct. 
Lenti:Non-targetshRNA (NT-shRNA2) in this backbone served as control.In the over-
expression construct, a 500 bp genomic fragment of miR-184 was cloned downstream to 
a CMV promoter for pre-miR-184 expression. In this construct the EF1 promoter drives 
GFP expression. C). Bright field (upper panel) and direct fluorescence (lower panels) 
showing expression of GFP as an indicator of transduction efficiency and a surrogate 
marker for shRNA or pre-miRNA expression (changes in the transcript levels of miR-184 
were also determined by qPCR). Control HL-1 cells, HL-1 cells transduced with Lenti-
NTshRNA, Lenti:miR-184shRNA and Lenti:pre-miR-184 are shown. D) FACS of HL-1 cells in 
the experimental groups showing gating strategy for GFP+ cells isolation. X-axis depicts 
the GFP fluorescence intensity and Y-axis cells side scatter. Green dots within the 
selected area represents the GFP+ cells that where collected for the subsequent 
experiments. E) Transduction efficiency in HL-1 cells infected with the recombinant 
Lenti-NTshRNA (71±18.3%), Lenti-miR-184shRNA (68±21%) and Lenti-pre-miR-184 
(48±25%) in four independent experiments. The transduced fraction, identified by GFP 
expression was used in the subsequent experiments. 
F) Quantitative PCR data showing 23±4.5 and 135±33 -fold increase in the 
expression levels of miR-184 in the control HL-1 and HL-1 cells transduced with Lenti-
Pre-miR-184  (N=3, *p<0.001). G) Expression levels of miR-184 upon transduction of 
HL1 myocytes transduced with Lenti:miR-184shRNA. As shown miR-184 transcript levels 
were reduced by 41±19% in Lenti:miR-184shRNA group, indicating effective knock down of 
miR-184 (N=3, *p=0.02). 
HL-1 cells were infected with Lenti-NTshRNA, Lenti-miR-184shRNA and Lenti-pre-
miR-184 followed by assessment of the transcript levels of the canonical Wnt and 
Hippo/YAP/TEAD pathway selected targets. H) Quantitative PCR analyses of the 
transcript levels of Axin2 and Ccnd1, established targets of the canonical Wnt signaling, 
showing no change upon over-expression or suppression of miR-184 levels (N=3, 
p>0.05). I) Quantitative PCR data on transcript levels of Hippo/TEAD/YAP downstream 
targets Ctgf and Cyr61 showing no change upon over-expression or suppression of miR-
184 levels (N=3, p>0.05). 
 Online Figure VI: miR-184 seed sequence paired with the 3’ UTR target sequence 
of genes involved in triglyceride synthesis: Schematic diagrams of binding sites of 
miR-184 in the 3' UTR of genes involved in the lipid biosynthesis. Mature miR-184 
sequence and Watson Crick pairing of 3′ UTR of Agpat1, Agapt3, Ncoa3, Ppargc1b and 
Dgat1 with miR-184 are also shown. Core of the miR-184 seed sequence is highlighted 
by a shaded rectangle. MiRNA target site ranking and conservation score where 
obtained from webtool at microrna.org and presented for each miRNA;target pair. 
 
Online Figure VII: Effect of control shRNAs on expression of selected miR-184 
targets and Cebpa: 
To rule out confounding effects of non-targeting shRNAs on miR-184 target gene 
expression, MPCs where transduced with lentiviruses expressing control shRNA used 
for knockdown experiment (Lenti-NTshRNA1 or NT-shRNA1) or overexpression 
experiments (Lenti-NTshRNA1 or NT-shRNA2).  A) QPCR analysis showed no difference in 
expression of Agpat1, Agpat3 and Cebpa in NT-shRNA controls as compared to the non 
transduced cells after 5 days of adipogenic stimulation. Knockdown or overexpression of 
miR-184 showed enhanced and reduced levels of corresponding RNAs (N=3, *p<0.05).  
 
 
 
ONLINE SUPPLEMENTARY TABLE I 
 
A. Primers for cloning of miR-184:  
184-F: 5’-GCTAGCGAATTCGGCTGGGAGTTTCTGTGTGTCT-3’                      
184-R: 5’-GGATCCGCGGCCGCGAACAGATCCTAAGCCCAGGT-3’ 
 
B. Primers for miR-184 promoter ChIP: 
miR-184-F-pro  CGGGAAACTGAGGCTCAAC 
miR-184-R-pro  AACCGTTCCGTTTACCACAG 
 
C. Primers for SYBR Green QPCR analysis: 
mmu-Rb1-Sybr-F1  ACCTGATAACCTTGAACCTGC 
mmu-Rb1-Sybr-R1  GCTTGTGTCTCTGTATTTGCAG 
mmu-Actb-Sybr-F1  ACCTTCTACAATGAGCTGCG 
mmu-Actb-Sybr-R1  CTGGATGGCTACGTACATGG 
mmu-Gapdh-Sybr-F1  CTTTGTCAAGCTCATTTCCTGG 
mmu-Gapdh-Sybr-R1  TCTTGCTCAGTGTCCTTGC 
mmu-DNMT1-Sybr-F1 CCACTAAACGGAAACCCAAGG 
mmu-DNMT1-Sybr-R1 CCTCTTCCAGTTTCTCCACAG 
mmu-DNMT3a-Sybr-F1 ACCACGGCAATTCCTTCTC 
mmu-DNMT3a-Sybr-R1 CTTCCTTTCGATCATCCTCCC 
mmu-DNMT3b-Sybr-F1 ACCACGGCAATTCCTTCTC 
mmu-DNMT3b-Sybr-R1 CTTCCTTTCGATCATCCTCCC 
hCcnd1-Sybr-F1  CCTCGGTGTCCTACTTCAAATG 
hCcnd1-Sybr-R1  GCGGTCCAGGTAGTTCATG 
hGapdh-Sy-F1  ACATCGCTCAGACACCATG 
hGapdh-Sy-R1  TGTAGTTGAGGTCAATGAAGGG 
 
 
D. Primers for bisulfite sequencing 
Bis-F1: 5’-GGGTTAATTGAATATTATTTTATGGGT-3’ 
Bis-R1: 5’-AAAAAAACTAACCTCAATCCAAAAC-3’ 
E. shRNAs 
NT-shRNA   SHC002     5’-CCGGCAACAAGATGAAGAGCACCAACTC-  
  GAGTTGGTGCTCTTCATCTTGTTGTTTTT-3’ 
Pkp2#1     TRCN0000123350       5’-CCGG-GCCTTGAGAAACTTGGTATTT-CTCGAG- 
               AAATACCAAGTTTCTCAAGGC-TTTTTG-3’ 
 
Pkp2#2      TRCN0000123351       5'-CCGG-CCTGAGTATGTCTACAAGCTA-CTCGAG-  
                    TAGCTTGTAGACATACTCAGG-TTTTTG-3' 
 
NT-shRNA1/2             5’-CTAAGGTTAAGTCGCCCTCGCTCTA 
             GCGAGGGCGACTTAACCTTAGGTTTTT-3’ 
 
Tcf4          TRCN0000012094       5'-CCGG-GCTGAGTGATTTACTGGATTT-CTCGAG- 
                             AAATCCAGTAAATCACTCAGC-TTTTT-3' 
 
Yap1     TRCN0000238436       5'-CCGG-TGAGAACAATGACAACCAATA-CTCGAG- 
            TATTGGTTGTCATTGTTCTCA-TTTTTG-3' 
 
Dnmt1    TRCN0000225697       5'-CCGG-TGAGAACAATGACAACCAATA-CTCGAG- 
            TATTGGTTGTCATTGTTCTCA-TTTTTG-3' 
 
Dnmt3A    TRCN0000039034    5'-CCGG-CCAGATGTTCTTTGCCAATAACTCGAG	
      TTATTGGCAAAGAACATCTGG-TTTTTG-3' 
 
Dnmt3B    TRCN0000071069     5'-CCGG-GCTCTGATATTCTAATGCCAACTCGAG 
           TTGGCATTAGAATATCAGAGC-TTTTTG-3 
 
F. Antibodies: 
Antibody Company Catalog Number Working dilution 
Plakophilin2       Progen      651101 1:300 
α-Tubulin Cell Signaling 2125 1:1000 
GAPDH Abcam     8245 1:10000 
YAP Cell Signaling 4912 1:1000(IB) 1:300(IF) 
TCF4 Cell Signaling 2569 1:1000 
FABP4 Cell Signaling 3544 1:1000(IB) 1:1000(IF) 
PPARγ Santa Cruz 7273 1:200(IF) 
CEBPA Cell Signaling 8178 1:500(IF)  
E2F1 Santa Cruz sc-193X 5ug/ChIP 
DNMT1 Active Motif 39204 5ug/ChIP 
NKX2.5 Santa Cruz sc-14033 1:1000 
Anti-Rabbit IgG, Alexa 
Fluor 594 
Life technology 21207 1:1000 
Anti-Mouse IgG, Alexa 
Fluor 594 
Life technology 21203 1:1000 
Anti-Rabbit IgG, HRP 
linked 
Cell Signaling 7074 1:2000 
Anti-Mouse IgG, HRP 
linked 
Cell Signaling 7076 1:3000 
V450 Mouse Lineage 
Antibody Cocktail, with 
Isotype Control 
BD Pharmingen 561301 20µl:106cells(FC) 
APC Anti-
Human/Mouse CD44  
eBioscience 17-0441-82 2µg:106cells(FC) 
PE Mouse Anti-Human 
CD140a 
BD Pharmingen 556002 1µg:106cells(FC) 
 
 
 
 
 
   
    
    
G. Taqman gene expression and microRNA assays (from life technology) 
Ankrd1  Mm00496512_m1 
Axin2   Mm00443610_m1 
Agpat1  Mm00479699_g1 
Agpat3  Mm00474003_m1 
Ctgf   Mm01192932_g1 
CyclinD1  Mm00432359_m1 
Cyr61   Mm00487499_g1 
Dgat1  Mm00515643_m1 
Dgat2  Mm00499536_m1 
Fabp4  Mm00445878_m1 
Gapdh  Mm99999915_g1 
Hes1  Mm01342805_m1 
Hey1  Mm00468865_m1 
Inhba   Mm00434339_m1 
Jup  Mm00550256_m1 
Lpl  Mm01345523_m1 
Ncoa3  Mm00500775_m1 
Pkp2   Mm00503159_m1 
Pparg  Mm01184322_m1 
Ppargc1b Mm00504720_m1 
hsa-miR-184  000485 
snoRNA202  001232 
hsa-miR-200b     002251 
mmu-miR-429     001077 
hsa-miR-188-5p  002320 
hsa-miR-487b    001285 
mmu-miR-881   002609 
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)
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
Bche 7.18765 0.182685 -5.29809 0
Rnf128 13.475 1.16229 -3.53524 0
Krt8 13.4598 1.22695 -3.45551 0
Acta1 21.2341 2.19407 -3.2747 0
Pgm5 16.8003 1.96903 -3.09293 0
Timp3 1.47509 0.217448 -2.76206 0
Cpne7 2.23906 0.352132 -2.6687 3.03E-09
Susd2 3.09541 0.527068 -2.55407 0
Slc12a8 1.48679 0.274184 -2.43898 6.91E-09
Camk2a 2.78699 0.657959 -2.08264 0.00000805
Alpk3 6.61629 1.69478 -1.96493 0
8430419L09Rik 3.77173 0.982668 -1.94045 0
Tspan12 24.2752 6.35904 -1.9326 0
Lifr 68.9826 20.0837 -1.78021 0
E330009J07Rik 1.47478 0.439042 -1.74807 3.82E-11
Foxo6 1.03285 0.330945 -1.64196 0.00000582
Itpr3 1.52355 0.501522 -1.60305 0.0000011
Epha4 6.82689 2.25461 -1.59835 0
Mmp15 7.19126 2.40599 -1.57961 0
Phf19 1.08629 0.368164 -1.56098 0.000044
Myo1e 1.35488 0.462543 -1.5505 1.4E-11
Gja1 40.8661 13.9774 -1.54781 0
Reep6 1.75803 0.604189 -1.54089 0.00030009
Des 166.135 58.4776 -1.5064 0
Plau 1.21106 0.426294 -1.50635 0.0000117
Dtna 3.60552 1.2871 -1.48608 5.69E-08
Reep2 1.59462 0.577592 -1.46509 0.00106525
Ttc39c 2.33354 0.846378 -1.46315 0.00000182
P2rx7 5.70427 2.1211 -1.42723 1.48E-09
Plxnd1 5.83042 2.36769 -1.30012 0
Fkbp1b 6.69655 2.73217 -1.29337 0.000000787
Fhl1 45.9353 18.7723 -1.291 0
Hspb6 15.3368 6.28087 -1.28796 1.52E-13
Homer1 14.9404 6.16123 -1.27792 0
B4galt5 14.9524 6.31875 -1.24267 0
Slc25a45 1.07376 0.458784 -1.22678 0.000863125
Camta1 3.94044 1.68675 -1.22411 0.00296505
Ctsb 43.1553 18.5806 -1.21574 0
Ppargc1b 2.2353 0.97627 -1.19512 7.43E-08
Wnk1 14.0242 6.16628 -1.18545 0
Differentially expressed miR-184 target genes
Average FPKM
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
Erc1 4.46447 2.04052 -1.12956 0
Ift81 21.9487 11.2211 -0.967923 0
Ppm1l 2.14053 1.10562 -0.953113 0.000015
Sfrs2ip 8.30357 4.36609 -0.927391 0
Notch3 1.40772 0.750137 -0.908139 0.00000203
Gmpr 19.1434 10.2531 -0.900785 9.97E-15
Slc25a13 7.12667 3.82016 -0.899594 1.47E-11
E2f2 2.74558 1.47449 -0.896893 9.45E-08
C230096C10Rik 10.5486 5.71959 -0.883066 3.49E-11
Plec1 8.87601 4.83008 -0.877864 0
Usp28 7.87013 4.32568 -0.863459 6.45E-12
Itsn2 38.9886 21.8394 -0.836117 0
Fyn 1.39747 0.786108 -0.830017 0.00571784
Fkbp1a 54.624 30.7503 -0.828933 6.13E-14
Ppp2r5a 84.1606 47.4009 -0.82823 0
Ncapd2 52.1172 29.6066 -0.815842 0
Pde4a 3.19065 1.82114 -0.809003 0.0000367
Tmem206 15.9482 9.16305 -0.799496 0.000023
Relt 1.73732 1.00561 -0.788796 0.0107498
Osbpl2 42.3954 24.6716 -0.781056 0
Gtpbp1 21.3908 12.5751 -0.766422 2.44E-14
Parvb 3.27314 1.9417 -0.753355 0.000000574
Pphln1 6.20395 3.70645 -0.743147 0.00000176
Arhgap1 39.3447 23.5983 -0.737488 2.04E-13
Ptpn1 10.5216 6.34852 -0.728854 2.48E-12
Gnai2 70.4007 42.7777 -0.71873 4.31E-14
Celsr1 1.31033 0.799046 -0.713578 0.000103875
Btg2 13.5459 8.30973 -0.704984 5.03E-11
Efnb3 11.7891 7.28746 -0.693969 3.06E-10
Nlgn2 1.23296 0.763012 -0.692353 0.0382146
Suv39h2 2.35694 1.48458 -0.666865 0.00471024
Aox1 3.23485 2.0424 -0.663434 0.0000587
Tspan9 28.8491 18.4191 -0.647324 5.38E-11
Gfod1 5.05447 3.2292 -0.646383 0.000000017
Rnf19a 6.45643 4.13549 -0.642678 3.39E-08
Plagl2 1.75117 1.1247 -0.638779 0.000611053
Cds2 12.9936 8.34736 -0.63841 2.04E-12
Shisa4 10.7935 6.94245 -0.636653 0.00244198
Egln3 2.15463 1.40127 -0.620708 0.00293974
Map3k7ip1 10.0817 6.57077 -0.617607 5.38E-08
Chmp4b 76.0544 49.6398 -0.615535 8.09E-12
Prdm16 1.10749 0.725943 -0.609367 0.0275819
Uros 6.63778 4.38663 -0.597588 0.0063327
Average FPKM
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
Rassf2 3.76131 2.48682 -0.596936 0.000201564
1110008F13Rik 82.0565 54.2787 -0.596233 0.000000233
Stom 40.9747 27.1166 -0.595557 4.87E-11
Agpat3 31.3299 21.224 -0.561839 0.0000202
Add3 61.3926 41.6302 -0.560433 0.00000001
Aes 119.153 80.977 -0.557234 3.7E-10
Rab22a 23.1848 15.8083 -0.5525 0.0000103
Abca2 3.90995 2.6662 -0.552367 0.0000692
Hap1 6.1726 4.2157 -0.550107 0.000821441
Phyhip 5.25173 3.59641 -0.546237 0.00177599
Mlf2 104.378 72.0158 -0.535432 1.05E-09
Adrm1 88.1664 61.0166 -0.531026 0.0000013
Gnas 276.045 191.265 -0.529328 0.000000235
Tmem65 12.2641 8.52289 -0.525024 0.00000474
Prepl 4.28386 3.00702 -0.51058 0.00543301
Ddx19b 3.29131 2.31734 -0.506191 0.0000498
Zfp217 2.60392 1.83642 -0.503787 0.014816
Clptm1 19.6691 13.8762 -0.503316 0.00000011
Grina 54.5078 38.5993 -0.497889 0.000000923
Flot2 20.9001 14.8178 -0.496181 0.0000017
Rap1gap 3.71311 2.63369 -0.495541 0.0497323
Herc3 7.57815 5.41718 -0.484302 0.000179938
Necap1 14.7376 10.5439 -0.483091 0.0000144
Dtd1 28.7091 20.5948 -0.47923 0.0000131
Ncoa3 6.91483 4.97248 -0.475729 0.00288118
Tnrc6b 4.08116 2.9566 -0.465038 0.0000113
Trak1 26.8557 19.5511 -0.457975 0.000255254
Eif2s2 82.4258 60.0259 -0.45751 0.000000423
Rttn 3.65003 2.65896 -0.457044 0.016585
Hexim1 3.74769 2.73294 -0.455552 0.00268384
Plekhb2 20.26 14.8364 -0.449493 0.00000583
Cdc25a 7.90853 5.79464 -0.448691 0.000947718
Qk 45.1224 33.0746 -0.448119 0.0000926
Abhd2 5.86796 4.31097 -0.444845 0.000330587
Dntt 9.27984 6.89315 -0.428937 0.0268039
Crlf3 11.576 8.63942 -0.422128 0.000994636
Impdh1 8.26037 6.17293 -0.420251 0.00228326
Bcl2l1 6.61097 4.94057 -0.420182 0.0162744
Ncam1 5.95839 4.46629 -0.415846 0.00221263
Ccdc47 25.5732 19.1693 -0.415832 0.0000587
P4ha2 15.2851 11.4591 -0.415632 0.000811737
Eif6 89.3775 67.1054 -0.413483 0.00000751
Pycrl 31.7469 23.931 -0.407733 0.000185982
Average FPKM
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
Otub2 8.79144 6.67148 -0.398093 0.0051228
Stat3 26.6951 20.2806 -0.396474 0.0000432
Tmbim1 32.8753 25.0106 -0.394466 0.00294546
Pxk 4.86869 3.74129 -0.379996 0.0209646
Ttc7 6.50792 5.01552 -0.375796 0.0178865
Ndrg3 9.82643 7.62726 -0.365503 0.00652351
Pif1 6.24946 4.86279 -0.361947 0.03434
Glod4 17.7501 13.8217 -0.360895 0.000800396
Tgm2 153.283 119.651 -0.357359 0.00038769
4930402H24Rik 8.55627 6.69332 -0.35426 0.00611627
Immt 100.744 78.8821 -0.352921 0.000847821
Fbxo5 12.2012 9.55714 -0.352372 0.0065312
Stxbp1 3.46954 2.72297 -0.349565 0.0454547
Ppp2r5c 32.8134 25.7968 -0.347093 0.00509571
5430437P03Rik 19.2244 15.1389 -0.344671 0.00346517
Fbxl14 8.31429 6.55489 -0.343022 0.00362404
Etv3 5.05205 3.98485 -0.342341 0.0294552
A830007P12Rik 4.6192 3.64918 -0.340071 0.0177828
Gpr107 7.53659 5.96096 -0.338367 0.0120154
Agpat1 22.1647 17.5468 -0.337052 0.00299628
Trpc4ap 26.558 21.2228 -0.323529 0.00147103
Rabac1 76.4841 61.1202 -0.323512 0.00222761
Sesn2 6.70153 5.37039 -0.319462 0.0355186
Fuca1 11.7854 9.51583 -0.3086 0.0105506
Tmco1 20.3214 16.4921 -0.301223 0.0021039
Efhd2 28.3418 23.0265 -0.299632 0.0035384
Snd1 65.9376 53.6005 -0.298856 0.00179138
Cpsf2 17.9054 14.6963 -0.284942 0.0398121
Ube2s 218.02 179.102 -0.28368 0.00348826
Vps28 39.7244 32.8968 -0.27208 0.0224055
Rnd3 25.898 21.472 -0.27038 0.00830042
Kif13a 8.18896 6.79208 -0.269826 0.041871
Rbm9 11.2996 9.39513 -0.266289 0.0225842
Map2k2 21.0763 25.4699 0.273169 0.0329056
Utp18 14.5414 17.5739 0.27327 0.0138249
Klf6 3.61879 4.40357 0.283163 0.0426405
Aldh9a1 5.43675 6.61758 0.28356 0.0414963
Fzd7 5.56072 6.77598 0.28516 0.0299117
Clspn 6.90761 8.43472 0.288153 0.0203161
Ezr 37.6539 46.093 0.291747 0.00489464
Igf1r 3.50723 4.29541 0.292466 0.0161783
Chst11 5.44226 6.69914 0.29977 0.0257837
Bri3bp 7.07894 8.72764 0.302057 0.00372025
Average FPKM
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
Mafk 7.88271 9.75648 0.30767 0.0129525
Khdrbs3 35.6764 44.1891 0.308721 0.00184476
Slc30a9 16.292 20.2784 0.315779 0.00180849
Tsen54 8.31619 10.3704 0.318482 0.0171115
Sdad1 6.88164 8.58401 0.318898 0.00364032
Gkap1 11.2729 14.0949 0.322314 0.0257262
Ppme1 13.0903 16.3706 0.322611 0.00416102
Mynn 5.41005 6.77289 0.324128 0.0161771
Dmtf1 6.88943 8.63541 0.32588 0.0300308
Lrba 4.50586 5.64973 0.32638 0.00578848
Stam2 4.92933 6.19835 0.330493 0.00784183
Kcne1 12.7449 16.063 0.333827 0.00757547
Csnk1g2 15.9732 20.1998 0.338687 0.00654851
Hist1h1d 57.2306 72.4386 0.339971 0.000296371
4933426M11Rik 4.96142 6.28594 0.341375 0.00370132
Grsf1 26.8789 34.1605 0.345851 0.000796476
Snip1 9.02986 11.4808 0.34645 0.0045251
Dhcr24 24.3793 31.0877 0.350685 0.000212991
Tfip11 4.608 5.87662 0.350847 0.00887897
Trim27 12.3214 15.7316 0.352499 0.00352907
Commd8 9.43025 12.0481 0.353443 0.00326279
Rhot1 10.6988 13.6842 0.355073 0.00354039
Srpk2 6.68819 8.57715 0.358882 0.00231383
Prkag2 17.5485 22.5327 0.360673 0.00802484
Cdk5rap2 8.64296 11.1187 0.36339 0.0011822
Ppp1cc 91.8111 118.227 0.364825 0.000108068
Angptl2 5.36597 6.92252 0.367459 0.00454977
Lzts2 13.7228 17.7626 0.372271 0.00328512
4930402E16Rik 6.59864 8.54369 0.372692 0.0228557
Fez2 9.1833 11.8907 0.37275 0.00277474
Hand2 35.2424 45.6481 0.373242 0.0000942
Stoml2 39.9616 51.8021 0.374395 0.000117519
Ehd1 13.1415 17.0679 0.377156 0.000249857
Prpf4 3.54253 4.62208 0.383762 0.00180725
Rab8b 4.55478 5.96006 0.387944 0.0011904
Gatad2b 3.68573 4.82435 0.388382 0.0029591
Snx27 5.36361 7.02758 0.389826 0.00357497
Cenpn 12.3774 16.2404 0.391877 0.000857838
0610007L01Rik 12.5688 16.5444 0.396496 0.000283719
Slc2a4 10.4982 13.8309 0.397753 0.000660017
S100pbp 7.01874 9.27879 0.402724 0.0187618
Adcy1 4.14109 5.47678 0.403316 0.000089
Rnf38 4.45878 5.8996 0.403967 0.0116983
Average FPKM
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
Hiat1 18.5944 24.6116 0.404474 0.0000476
Clcn7 10.085 13.3627 0.406 0.000339104
Chn2 2.86535 3.81855 0.414317 0.00788841
Ptma 494.34 661.475 0.420185 0.000352282
Siah2 4.33343 5.80164 0.420951 0.00540006
Zbtb5 4.28377 5.73626 0.421229 0.00511846
Mesdc2 14.4489 19.3804 0.423633 0.00000821
Zfp523 3.23738 4.34472 0.42444 0.0233668
Foxj3 3.76025 5.05006 0.425471 0.004748
Rsu1 22.4104 30.1662 0.428762 0.0000538
Rprd1a 11.0659 14.9217 0.431293 0.000888883
Lrrc40 9.09783 12.2794 0.432646 0.000052
Ap2m1 85.454 115.406 0.433503 0.0000277
Uso1 7.35254 9.93125 0.433732 0.0488176
Lasp1 5.90933 7.98442 0.434191 0.000615207
Ctdsp2 9.25499 12.5682 0.441474 0.000041
1110007L15Rik 25.3471 34.4267 0.441707 0.0000067
Pkd1 3.02045 4.10483 0.442559 0.000100402
Cisd2 11.3547 15.4399 0.44337 0.000032
Lrrc8a 5.26049 7.15393 0.443537 0.000349672
Git1 5.76638 7.86489 0.447761 0.00034135
Prps2 13.1199 17.8994 0.448155 0.00000535
Tmem38b 5.21345 7.12526 0.450705 0.00226968
Map3k7ip3 2.17961 2.98339 0.452885 0.010106
Ndel1 22.2054 30.4238 0.454289 0.0000112
Dgcr2 12.4284 17.0328 0.45467 0.0000372
Slc38a7 3.22256 4.42308 0.456844 0.0232542
Cdc42se1 11.7828 16.1752 0.457096 0.0166723
Sec24a 1.68479 2.31976 0.461405 0.0178956
Depdc5 4.03246 5.55242 0.461457 0.00259283
Gsk3b 4.55819 6.3074 0.468585 0.00000237
Trim33 3.40074 4.71093 0.470165 0.0000746
Lrp5 3.42889 4.76555 0.474899 0.0000717
Qtrtd1 3.30968 4.60913 0.477804 0.0116028
Nhlrc3 2.57938 3.59672 0.479659 0.0285968
Nav1 1.61206 2.2504 0.481272 0.000808437
Stx4a 7.07951 9.90182 0.484044 0.00103332
Sh3bgrl 18.4929 25.9037 0.486192 0.0000028
Gosr2 21.6459 30.4314 0.491466 0.000000203
Magi3 20.9888 29.5984 0.495898 0.000000159
Tmem9b 17.6794 24.9734 0.498326 0.00000344
Alg2 2.60922 3.68817 0.499285 0.0217726
Average FPKM
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
Psd3 2.99693 4.25742 0.506492 0.0000113
Golga7 22.1062 31.4288 0.507634 0.00000456
Ube2b 12.4352 17.7028 0.509553 0.0000912
Eif4ebp1 132.455 189.434 0.516189 1.13E-08
Acaca 10.342 14.8388 0.520867 0.000000012
Nsun2 11.3894 16.3433 0.521001 4.82E-08
Ppm1f 8.85045 12.7059 0.52168 0.000000667
Stat5a 3.89012 5.60474 0.526832 0.000409877
Arl13b 1.74948 2.52115 0.527153 0.0131759
Med28 18.4746 26.6465 0.528404 0.0000227
Hspb8 74.1552 106.972 0.528616 4.64E-09
Ubn1 7.68909 11.1048 0.530299 0.00000149
Prkx 3.11768 4.50421 0.530799 0.000141575
Vti1a 3.79004 5.49522 0.535966 0.0101381
Rufy3 3.41061 5.00296 0.552753 0.00010987
Rcc1 14.8404 21.7885 0.554033 0.000000691
Vac14 10.8879 15.9871 0.554183 4.19E-08
Atp8a1 1.15358 1.69707 0.556929 0.00382542
Ankrd27 6.23947 9.18958 0.558575 0.0000506
Cog2 10.9619 16.1836 0.562036 0.000000622
Csf1 2.93014 4.3338 0.564663 0.00111966
Rhobtb1 5.193 7.71348 0.570814 0.0000389
Sppl3 7.30415 10.8599 0.572224 0.000000808
Zfx 6.01484 8.95205 0.573692 0.000000964
Phka1 4.4586 6.64111 0.574835 6.04E-08
Stx2 4.59373 6.87874 0.582479 0.0000837
Tshz1 7.8165 11.7441 0.587346 1.88E-10
Slc25a23 3.98215 5.9858 0.587995 0.00000251
Slc35d1 1.21917 1.83434 0.589362 0.0147459
Zc3h18 20.4354 30.769 0.590403 4.25E-09
Myo1c 21.8872 32.9665 0.590911 7.06E-09
Vps33a 9.3297 14.076 0.593333 2.65E-08
Sntb2 10.6918 16.1459 0.594665 0.000000725
Stag1 5.15035 7.78656 0.596317 4.14E-08
Klhl30 17.1329 25.9396 0.59839 3.91E-10
Ntan1 16.9553 25.6738 0.598565 0.0120666
Golm1 9.24917 14.024 0.600496 2.12E-09
Smarca2 5.72859 8.74303 0.609953 0.0000104
Cyp26b1 3.24365 4.95423 0.611044 0.000215367
Mllt3 2.25428 3.44633 0.612394 0.000000915
BC026590 1.35679 2.07722 0.614459 0.0309912
Zc3hav1l 1.235 1.89703 0.619226 0.00193683
Tgds 2.77539 4.27181 0.622159 0.000837248
Average FPKM
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
E130308A19Rik 2.51454 3.87142 0.622569 0.00097306
Amotl2 7.59634 11.6992 0.623032 3.03E-09
Tcfap4 2.42517 3.73932 0.624688 0.000559256
Ulk1 2.6981 4.17013 0.628147 0.0000123
Ddc 4.34114 6.71783 0.629921 0.0209351
Pitpnm2 2.40873 3.72907 0.630542 0.0000326
Zmym3 6.15621 9.54036 0.632002 0.000238875
Ssr4 63.1764 97.9716 0.632978 0.000924503
Slc6a9 2.76266 4.2863 0.633674 0.000543717
Cggbp1 18.3801 28.5347 0.634569 1.41E-10
Akap12 5.31297 8.26123 0.636839 6.25E-11
Lgr6 1.75462 2.7312 0.638378 0.00204083
Pdzd11 19.0583 29.7085 0.640453 2.48E-08
Zyx 7.50933 11.8415 0.657095 0.00000148
D16H22S680E 6.82468 10.7687 0.658011 0.000251981
Lpp 5.715 9.06197 0.665071 0.0000152
Eif4ebp2 3.72194 5.91511 0.66835 2.08E-08
Rab3d 3.91844 6.23315 0.669683 0.000000373
Slc7a5 33.8847 53.9569 0.671171 6.13E-14
Ube2a 5.99807 9.5643 0.673161 0.00000244
1600021P15Rik 2.70222 4.31177 0.674132 0.00000493
Nhlrc1 0.708634 1.13532 0.679993 0.0293141
Galnt2 49.5119 79.354 0.68053 2.39E-13
Arhgef7 10.1573 16.3109 0.68332 8.11E-10
Trim2 9.48078 15.2279 0.683638 4.85E-09
Arl8b 21.9304 35.2698 0.685504 8.39E-14
Gca 3.6729 5.91609 0.687725 0.00000479
Evc2 2.31374 3.73256 0.68994 0.000120975
Trim32 3.6717 5.92368 0.690045 0.0000778
Unc5b 2.11803 3.42076 0.691595 4.79E-08
Smap1 5.10739 8.25614 0.692881 0.000000213
Xiap 3.8873 6.292 0.694749 9.73E-09
Hspa12a 1.37513 2.22916 0.696929 0.0000416
1110003E01Rik 14.1719 23.001 0.698659 6.36E-09
Rap2c 4.28078 6.94812 0.69875 0.00000389
Tmco4 3.8143 6.20056 0.700978 0.0000036
Cyb5b 85.6909 140.642 0.71481 3.88E-13
2310079N02Rik 14.3283 23.55 0.716864 0.000000554
Gm672 0.633588 1.04511 0.722039 0.00740348
Prkacb 9.1291 15.0611 0.722279 2.43E-13
Phc2 6.82271 11.3158 0.729923 2.03E-08
Nkap 2.58239 4.287 0.731263 2.24E-08
Rab35 13.0823 21.7274 0.731895 1.2E-12
Average FPKM
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
Anp32b 18.0306 30.3016 0.748946 2.9E-13
Ubap2 4.29899 7.24903 0.753791 2.22E-10
B3galtl 4.68305 7.90049 0.754493 0.000574043
Ikzf2 0.600872 1.01535 0.756848 0.00182296
Frmd4a 1.75317 2.97443 0.762648 0.0000274
Arid5b 0.874966 1.49693 0.774706 0.000273738
Psip1 30.4575 52.1098 0.774759 7.25E-12
Lmln 1.09753 1.87886 0.775593 0.00134896
Acp1 37.6977 64.5909 0.776853 3.84E-14
Tns3 5.04133 8.65095 0.779055 8.75E-10
Ndst1 10.3663 17.7921 0.779328 5.86E-08
Dlg1 8.97271 15.4104 0.78029 1.29E-13
Zfp777 1.7013 2.92336 0.780989 0.000961136
Dcun1d3 1.53924 2.64866 0.783043 0.0000367
Clec16a 4.71317 8.11649 0.784159 0.000000221
Man2a1 21.9623 37.8567 0.785522 0
E130012A19Rik 0.896076 1.54743 0.788178 0.00419915
Zmiz1 3.90357 6.75544 0.791257 1.86E-11
Polr2h 15.4563 26.9964 0.804567 5.29E-10
Syngr1 59.6451 104.178 0.804573 2.77E-12
Zdhhc7 15.8681 27.7296 0.805302 0
Rab1 17.0928 29.9282 0.808118 2.9E-13
Fmnl3 1.86109 3.27672 0.8161 0.00000189
Tpcn1 1.81871 3.21064 0.819949 4.63E-09
Src 2.38475 4.21674 0.822287 0.000000819
Unc119b 12.7833 22.7393 0.830928 0
Nkrf 1.43065 2.55094 0.834358 0.0000878
Eif2c1 1.62511 2.90242 0.836719 2.2E-09
Abcd3 15.4632 27.752 0.843755 0
Ebna1bp2 15.4597 27.7592 0.84445 0
Numbl 1.78365 3.2046 0.845313 0.0000513
Itsn1 10.9789 19.8432 0.853914 0
Cmtm4 34.6902 63.0881 0.86284 8.85E-09
Slc36a1 1.77944 3.23858 0.863942 0.000000039
Arcn1 55.9444 102.189 0.869176 0
Man1c1 4.125 7.58175 0.878137 0
Wwc2 8.44927 15.5533 0.880325 0
Ap3m1 20.8433 38.8272 0.897481 0.0000256
Plekhh2 1.22372 2.30248 0.91192 8.17E-12
B4galt1 19.2274 36.8513 0.938552 0
Ankrd52 2.28336 4.38337 0.940879 3.41E-13
Prkab2 2.23211 4.31122 0.94969 0.000000026
Tmeff1 1.75827 3.4029 0.95261 0.000581989
Average FPKM
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
Rragc 13.616 26.8488 0.979552 0
Fdxr 5.93116 11.7548 0.986863 1.14E-12
Pldn 2.9115 5.81315 0.997559 4.58E-12
Ets2 1.45826 2.91833 1.0009 6.92E-10
Ifnar1 5.44487 10.9245 1.0046 0
Zmat3 1.82303 3.70689 1.02387 0
Fkbp10 2.99023 6.08279 1.02448 0.000000141
Tbc1d1 17.4479 35.5546 1.02699 0
Dcun1d4 2.55462 5.2147 1.02947 4.09E-12
Tsr2 3.74483 7.78295 1.05542 0
Emp1 6.37309 13.2902 1.06029 0
Eomes 1.37992 2.87835 1.06066 2.82E-08
Gpr173 0.730241 1.5334 1.07029 0.000193332
Mkl1 0.990183 2.08555 1.07466 0.000000273
Hadh 24.97 52.7265 1.07833 0
Smad1 4.84538 10.2973 1.08759 0
Lnx1 6.92823 14.8936 1.10413 1.04E-10
Hyou1 71.1844 153.51 1.1087 0
Slc46a1 1.00192 2.21289 1.14316 0.00000645
Rab3il1 1.02032 2.26818 1.15251 0.00000261
Smad9 1.14491 2.57333 1.16841 3.63E-11
Chst12 2.62819 5.99552 1.18982 7.72E-09
Swap70 7.49665 17.3222 1.2083 0
Tpm2 98.7529 228.234 1.20862 0
Sh3d19 1.64833 3.83051 1.21653 0
Adcy9 0.767446 1.83414 1.25697 0.00000401
Trdmt1 1.21295 2.90562 1.26033 0.000000334
Dapk1 2.73712 6.61069 1.27214 0
Zcchc14 3.91959 9.73433 1.31238 7.21E-11
2310022B05Rik 24.0457 59.7878 1.31407 0
Rgl1 4.58922 11.4586 1.32011 0
Fzd2 4.4711 11.1768 1.3218 0
Dact3 4.28795 10.811 1.33413 0
Serinc5 2.86411 7.37083 1.36374 0
Nfyc 15.079 39.0877 1.37418 0
Zc3h12a 0.473779 1.25035 1.40004 0.000546588
Eif5a2 6.3424 16.9485 1.41805 0
Zfp704 0.837377 2.28699 1.4495 0
Klhl24 8.04856 22.1236 1.45879 0
Foxo1 0.528515 1.48563 1.49106 2.93E-10
Pink1 9.75375 27.9903 1.5209 0
Col4a4 7.27376 22.0527 1.60018 0
9030224M15Rik 0.35314 1.20048 1.7653 0.0000888
Average FPKM
Gene HL-1Pkp2shRNA HL-1WT Log2(fold_change) q_value
Cabp1 1.18317 4.47632 1.91966 6.59E-09
Mmp14 5.81187 22.6551 1.96276 0
Emilin1 1.4939 5.9846 2.00217 0
Tgfb2 1.12864 4.55554 2.01304 0
Etv5 1.54098 6.38705 2.0513 0
Hs3st3b1 0.580553 2.57901 2.15132 0
Runx1 0.930973 4.55359 2.29019 0
Nipsnap1 0.832757 4.31912 2.37477 0
Gper 0.665631 3.56461 2.42095 8.17E-10
Ppap2b 3.0782 17.8475 2.53556 0
Rasgef1b 1.5352 9.19842 2.58296 0
Crispld2 0.42764 2.64117 2.62671 4.91E-11
Mcf2l 1.57594 11.5779 2.87709 0
Igfbp4 6.85319 53.3595 2.9609 0
Reck 0.56863 4.61862 3.0219 0
Lypd1 0.18629 1.95914 3.3946 5.68E-08
Ltbp1 0.15593 1.71335 3.45785 0
Tmem86a 1.12874 13.6796 3.59924 0
Arhgdib 1.25911 26.747 4.4089 0
Eln 0.0409468 1.18427 4.85411 8.73E-12
Average FPKM
Online TABLE III 
Echocardiographic Data 
 
 Wild type Pkp2shRNA (no 
promoter) 
Nkx-2-5-Cre:Pkp2shRNA p 
N 12 12 19  
Male/Female 6/6 5/7 9/10 0.915 
Age (months) 9.0±2.1 8.4±1.5 8.1±0.9 0.284 
Body weight (g) 32.7±3.6 35.5±4.3 33.9± 4.3 0.267 
HR (bpm) 565± 106 582 ±84 576±70 0.885 
IVST (mm) 0.99 ±0.11 0.92± 0.16 0.76± 0.06* ≤0.001 
PWT (mm) 0.99± 0.07 0.94± 0.07 0.73 ±0.08* ≤0.001 
LVEDD (mm) 3.01±0.26 3.20±0.22 3.80± 0.46* ≤0.001 
LVEDDi (mm/g) 0.09±0.11 0.09±0.01 0.11± 0.02* ≤0.001 
LVESD (mm) 1.07±0.22 1.26± 0.30 2.10± 0.55 ≤0.001 
FS (%) 64±6 61±9 46±9* ≤0.001 
LVM (mg) 85±27 98±22 95±19 0.358 
LVMi (mg/g) 2.6±0.8 2.8±0.5 2.8±0.5 0.753 
 
Abbreviations: Pkp2shRNA: shRNA against Pkp2 mRNA without a promoter; Nkx-2-5-Cre:Pkp2shRNA: shRNA 
against Pkp2 mRNA expressed under the transcriptional control of Nkx2-5 promoter. HR, heart rate; bpm, 
beats per minutes; IVST, interventricular septal thickness; PWT, posterior wall thickness; LVEDD, left 
ventricular end diastolic diameter; LVEDDi, LVEDD divided for the body weight; LVESD, left ventricular end 
systolic diameter; FS, fractional shortening; LVMass, left ventricular mass; LVMi, LVMass divided for the 
body weight.*p≤0.005 vs WT and Nkx2-5-Cre:Pkp2shRNA. 
	
	
	
Number of CpGs  analyzed 15
Number of clones used for  bisulfite sequencing (HL-1) 17
Number of clones used for bisulfite sequencing  (HL-1Pkp2-shRNA) 20
CpG position 1 58
Number of methylated CpGs (HL-1) 4 5
Number of CpGs (HL-1) 17 17
ratio of methylation (%) (HL-1) 23.5 29.4
Number of methylated CpGs (HL-1Pkp2-shRNA) 16 20
Number of CpGs (HL-1Pkp2-shRNA) 20 20
ratio of methylation (%) (HL-1Pkp2-shRNA) 80 100
Number of methylated CpGs (total) 20 25
Number of CpGs (total) 37 37
ratio of methylation (%) (total) 54.1 67.6
P-value of Fisher's exact test 0.000913 3.34E-06
P-value of Mann-Whitney U-test 0.000001
S.D. of % methylated (between CpGs, HL-1) 10.3
S.D. of % methylatied (between sequences, HL-1) 35.8
S.D. of % methylatied (between CpGs,HL-1Pkp2-shRNA) 7.1
S.D. of % methylatied (between sequences, HL-1Pkp2-shRNA) 4.3
S.D. of % methylatied (between CpGs, total) 7
S.D. of % methylatied (between sequences, total) 43.1
Upper limit of unconverted CpHs 5
Lower limit of percent converted CpHs 90.00%
Upper limit of alignment mismatches 25
Lower limit of percent identity 90.00%
Summary of information
Condition to exclude low quality sequences
Methylation status of each CpG site
151 156 177 183 187 192 221 281
5 5 8 5 5 5 3 2
17 17 17 17 17 17 17 17
29.4 29.4 47.1 29.4 29.4 29.4 17.6 11.8
18 20 19 20 20 20 18 20
20 20 20 20 20 20 20 20
90 100 95 100 100 100 90 100
23 25 27 25 25 25 21 22
37 37 37 37 37 37 37 37
62.2 67.6 73 67.6 67.6 67.6 56.8 59.5
0.00021 3.34E-06 0.00198 3.34E-06 3.34E-06 3.34E-06 1.06E-05 1.45E-08
Methylation status of each CpG site
287 304 357 371 385 Total
3 1 3 2 3 59
17 17 17 17 17 255
17.6 5.9 17.6 11.8 17.6 23.14
20 18 18 16 19 282
20 20 20 20 20 300
100 90 90 80 95 94
23 19 21 18 22 341
37 37 37 37 37 555
62.2 51.4 56.8 48.6 59.5 61.44
1.11E-07 1.95E-07 1.06E-05 4.73E-05 1.47E-06 9.90E-73
Methylation status of each CpG site
